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PUPILLARY LIGHT REFLEX DEFICITS IN A CANINE MODEL OF 
NEURONAL CEROID LIPOFUSCINOSIS AND THE EFFECTS OF ENZYME 
REPLACEMENT THERAPY 
 
Rebecca E.H. Whiting 
 
Drs. Martin L. Katz & Kristina Narfström, Dissertation Supervisors 
ABSTRACT 
Pupil size is controlled by the autonomic nervous system, and iris behavior 
reflects a balance of input from both the sympathetic and parasympathetic 
nervous systems.  The pupillary light reflex (PLR) occurs in response to light 
entering the eye and requires functional integrity of the retina and specific nuclei 
of the midbrain.  Recently, pupillography or quantitative analysis of the PLR has 
been developed as a non-invasive, objective technique capable of detecting 
subtle changes associated with the complex network of neuronal circuitry 
involved in modulating pupil size.  This makes the PLR a useful biomarker that 
can be used to monitor disease progression in neurological disorders.   
The neuronal ceroid lipofuscinoses (NCLs) are a group of lysosomal storage 
disorders that are inherited in an autosomal recessive manner.  A late-infantile 
onset form of NCL (CLN2) is caused by a mutation in the CLN2 gene which 
codes for tripeptidyl peptidase-1 (TPP1), a soluble, lysosomal enzyme that aids 
degradation of peptides in cells throughout the body. A Dachshund model of 
CLN2 was developed and is currently being maintained at the University of 
Missouri.  Dogs affected by CLN2 lack functional TPP1 and present with 
xvi 
 
progressive ataxia, cognitive and behavioral changes, and myoclonic seizures 
starting at approximately 7-8 months of age and progressing to a terminal state 
requiring euthanasia at 10 to 11 months of age.  In addition, affected dogs 
exhibit vision loss and marked deficits in ERG b-wave amplitude and significant 
thinning of the inner retina by disease end-stage.  The strong resemblance to 
the human CLN2 makes these dogs an excellent model in which to test possible 
treatment options prior to beginning human clinical trials. 
 
In the effort to make optimal use of the canine model of CLN2, studies were 
undertaken to develop a reliable protocol for the quantitative assessment of the 
canine PLR.  Using the developed equipment and methodology, we thoroughly 
evaluated the PLR in response to short flashes of white light of increasing 
intensity in normal and CLN2-affected dogs.  We found that CLN2-affected dogs 
exhibit PLR deficits that progress with age and other symptoms of disease.  
Deficits are particularly apparent with dim stimuli and likely result from a 
combination of decline in retinal function and disease related changes in areas 
of the midbrain involved in modulating the PLR. 
In the Dachshund CLN2 disease model, it was previously shownthat 
administration of recombinant TPP1 via infusion into the cerebrospinal fluid 
(CSF) results in widespread distribution and uptake of the active enzyme into 
many structures of the brain and in reduction in the accumulation of neuronal 
lysosomal storage material that is characteristic of this disease.  Studies were 
undertaken to determine if TPP1 enzyme replacement therapy (ERT) could 
xvii 
 
ameliorate PLR deficits associated with CLN2.  One-third of the dogs treated 
with ERT exhibited a substantial delay in the appearance of PLR deficits 
compared with untreated, affected dogs.  However, no improvements in retinal 
function could be measured by the ERG.  It is unlikely that TPP1 reached the 
retina, and it is more likely that ERT normalized the PLR by preventing 
degeneration in areas of the midbrain involved in modulating the PLR.  
However, further analysis of retinal and midbrain tissues is necessary to fully 
explain these treatment effects.   
The characterization of disease-related alterations in light induced responses 
contributes to our understanding of the pathology underlying CLN2.  Preventing 
development of the deficits in the PLR and ERG responses can be used to 
objectively assess the efficacy of therapeutic interventions for CLN2 that are 
currently being evaluated.  An ideal therapy would prevent the declines in both 
the PLR and the ERG responses by preventing both retina and brain 
degeneration.         
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CHAPTER 1  
INTRODUCTION AND BACKGROUND 
1.1. The Pupillary Light Reflex 
1.1.1 Pupillary Responses 
The iris of the mammalian eye regulates the amount of light that reaches the 
retina by modulating the size of the opening at the center of the iris called the 
pupil.  Pupil size is controlled by the autonomic nervous system, and therefore 
iris behavior reflects the function of both the sympathetic and parasympathetic 
nervous systems.  The iris consists of two sets of antagonistic smooth muscles, 
one for constriction and the other for dilation (Figure 1-1).  The parasympathetic 
system releases acetylcholine to both activate the circularly arranged sphincter 
muscles and to inhibit the muscles responsible for dilation allowing constriction to 
occur more rapidly and to a greater extent.  The sympathetic system releases 
norepinephrine which activates the radially arranged dilator muscles and also 
inhibits the constrictor muscles (Yoshitomi and Ito 1986; Yoshitomi, Ito, and 
Inomata 1985).  The size of the pupillary opening at any moment is determined 
by the balance between the sympathetic and parasympathetic input to the iris 
muscles.   
2 
 
 
Figure 1-1: Autonomic control of pupil size through innervation of the iris 
muscles.      
 
Pupil size changes in response to many types of stimuli including noise, pain, 
surprise, pleasure and stress which all cause pupil dilation from activation of the 
sympathetic nervous system (Bradley et al. 2008; Lowenstein and Lowenfeld 
1950).  Cognitive tasks can also cause pupil dilation through cortical inhibition of 
parasympathetic input to the iris muscles (Steinhauer et al. 2004).  However, the 
most prominent factor regulating pupil size is the amount of light that enters the 
eye.  The retina has a limited dynamic range.  To help keep the amount of light 
reaching the retina within this range, pupil size is reduced under bright light 
conditions and is increased under dim light conditions.  These changes in pupil 
size in response to alterations in light exposure are called the pupillary light reflex 
(PLR). 
Mammals have both a direct PLR of the stimulated eye, and a consensual 
PLR of the contralateral, unstimulated eye (Scagliotti 1999).  The dynamics of the 
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PLR vary depending on the characteristics of the light stimulus, such as intensity, 
duration, and color.  The PLR is also known to change with conditions that affect 
the autonomic nervous system including disease and trauma.   This makes the 
PLR a non-invasive biomarker that can be used to monitor neurological status.  
1.1.2 Retinal Input to the PLR 
The signal to initiate the PLR begins in the light sensitive elements of the 
retina, consisting of rod and cone photoreceptors and intrinsically photosensitive 
retinal ganglion cells (ipRGCs) (Markwell, Feigl, and Zele 2010; Gamlin et al. 
2007; Dacey et al. 2005a).  The ipRGCs contain the photopigment melanopsin, 
which allows them to independently collect information about overall light levels 
in the environment and project to centers of the brain responsible for the PLR 
and circadian photoentrainment (Brown and Lucas 2009).  All rod and cone input 
to the PLR is routed through the ipRGCs where input from all three cell types is 
combined and transmitted to the areas of the midbrain responsible for the PLR 
(Ecker et al. 2008).  Genetically modified mouse models have demonstrated that 
rods, cones, and ipRGCs are all essential to a fully normal PLR (Lucas et al. 
2003; Hattar et al. 2003).  In mice lacking the melanopsin photopigment but with 
intact ipRGC neural connections, the pupil is unable to fully constrict at high 
irradiances.  Loss of the rod and cone system results in an increased threshold 
and reduced constriction amplitude with all stimuli except those of very high 
intensity (above 14 log photons/cm2/s) (Lucas et al. 2003).  When ipRGCs are 
ablated, animals lose non-image forming visual function including the PLR and 
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circadian entrainment.  However, since this neural pathway is separate from that 
required for image forming vision, animals lacking ipRGCs retain pattern vision 
(Ecker et al. 2008).      
1.1.3 PLR Neural Pathway 
The pathway for parasympathetic input of the PLR (Figure 1-2) originates in 
the light-sensitive elements of the retina, including rods, cones, and intrinsically 
photosensitive melanopsin ganglion cells (Gamlin et al. 2007; Markwell, Feigl, 
and Zele 2010).  The signal from the retina is conveyed in the optic nerve 
through the optic chiasm and optic tract.  Axons in the optic tract not involved 
with vision diverge from the visual pathway at the lateral geniculate nucleus to 
the pretectal nuclei at the level of the midbrain.  The majority of axons of the 
pretectal nuclei cross to synapse on the contralateral neurons of the oculomotor 
nerve nuclei, which provide the parasympathetic innervations to the pupil.  Some 
axons of the pretectal nuclei remain ipsilateral.  Axons from the parasympathetic 
nuclei course in the oculomotor nerve and synapse in the ciliary ganglion.  
Postganglionic neurons from the ciliary ganglion innervate the constrictor muscle 
of the pupil via the short ciliary nerve.  Stimulation results in constriction of the 
pupil.  There is bilateral input to the pretectal nuclei and therefore bilateral 
projections to the autonomic division of the oculomotor nuclei.  Thus, light 
directed into one eye results in constriction of both pupils.   In addition, the 
parasympathetic system can be centrally inhibited at the parasympathetic 
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division of the oculomotor nucleus (Dahlstrom et al. 1964; Lawrence G. Sharpe 
and Pickworth 1981). 
 
 
Figure 1-2:  Parasympathetic pathway of the pupillary light reflex.  Input 
originates in the light sensitive elements of the retina, projects bilaterally to the 
pretectal nuclei, which each project bilaterally to the parasympathetic division of 
the oculomotor nuclei.  Fibers project in the oculomotor nerve to the ciliary 
ganglion, and short ciliary nerves innervate the iris muscles.  Modified figure 
from Dr. Dennis O’Brien.     
 
Pathways for sympathetic input to the PLR (Figure 1-3) originate in the 
hypothalamus and axons course ipsilaterally down the brainstem and cervical 
spinal cord via the lateral tectotegmental tracts to synapse on lower motor 
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neurons located in the intermediate gray matter of the spinal cord segments T1 
through T3 (Scagliotti 1999).  Preganglionic (first order neurons) fibers leave the 
spinal cord and project as the cranial sympathetic trunk, which courses cranially 
in the neck synapsing in the cranial cervical ganglion.   Finally, postganglionic 
sympathetic axons (second order neurons) then follow other cranial nerves to 
innervate structures in the head.  Sympathetic nerves innervate smooth muscle 
in the periorbital facia, other structures around the eye and the dilator muscles of 
the iris.   
 
Figure 1-3:  Pathway for sympathetic input to the PLR in the dog.  
 Axons of both sympathetic and parasympathetic nerves enter the periorbital 
region through the orbital fissure and travel through the choroid to the iris.  Pupil 
size is ultimately determined by the balance of input from these two systems 
(Lowenstein and Lowenfeld 1950).  
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1.2. Applications of PLR Quantification 
Assessment of the pupillary light reflex (PLR) has long been used to assist in 
disease diagnosis for both human and veterinary medicine (Wilhelm 2008; 
Bremner 2009).  However, classical methods of evaluating pupil abnormalities 
are largely qualitative and can only be used as a discriminating measure when 
substantial deficits are present.  Recently, pupillography or quantitative analysis 
of the PLR has been developed as a non-invasive, objective technique capable 
of detecting subtle changes associated with the complex network of neuronal 
circuitry involved in modulating pupil size (Park et al. 2011; F. Fotiou et al. 2000).  
In addition to its use in the study of retinal disease (Thompson et al. 2010; 
Grozdanic et al. 2007; Melillo et al. 2012), pupillography has been used to detect 
autonomic dysfunction in neurologic disorders including multiple sclerosis (De 
Seze et al. 2001), Alzheimer’s disease, Parkinson’s disease (Fotiou et al. 2009), 
and autism spectrum disorders (Fan et al. 2009a).  Quantification of specific PLR 
parameters (Figure 1-4) in these studies allowed for the analysis of small but real 
changes that may not have been detectable upon gross observation.  
1.2.1 PLR Parameters 
The PLR parameters that are typically considered are illustrated in Figure 1-4.  
For the studies described here, baseline pupil diameter is the average pupil 
diameter in a dark-adapted dog, over a 1-second period before the light stimulus. 
PLR constriction amplitude is defined as the difference between baseline pupil 
diameter and minimum pupil diameter attained following a light stimulus.  Latency 
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is defined as the time between stimulus onset and the beginning of pupil 
constriction.  Average constriction velocity is calculated as the constriction 
amplitude divided by the constriction time, where constriction time is calculated 
between the beginning of pupil constriction and the minimum pupil diameter.  
Redilation of the pupil is biphasic with a fast initial redilation and slower 
secondary redilation.  Average redilation velocity is defined as half the 
constriction amplitude divided by the time required for the pupil to redilate from its 
minimum diameter to half the baseline pupil size.  The post illumination pupil 
response (PIPR) is calculated as the difference between baseline pupil diameter 
and sustained pupil diameter, or the average diameter for a defined period during 
the secondary redilation phase.   
 
Figure 1-4: Pupillogram showing the characteristic change in pupil area after a 
100 millisecond stimulus.  PLR parameters of interest can be calculated as 
indicated. 
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1.3. Electroretinography 
The electroretinogram (ERG) is a recording of the electrical potential 
generated by the retina in response to a light stimulus.  This potential can be 
detected non-invasively by placing a contact electrode on the cornea and a 
reference electrode on or under the nearby skin.  Since the generated potential 
reflects the function of underlying cells, it is possible to monitor the amplitude and 
timing of this response for abnormalities as a measure of functional integrity of 
the cells.  For this reason, the ERG is commonly used as a diagnostic tool in 
human and animal cases of retinal degeneration. 
 
The ERG waveform has characteristic components depending on the 
parameters of the light stimulus.  The early negative component of the ERG is 
called the a-wave (Figure 1-5) and reflects activity of the retinal photoreceptor 
cells (Penn and Hagins 1969).  When a photon of light is absorbed in the 
photoreceptor outer segments, a transformational change occurs in the opsin 
molecules, or photopigments, which initiates a cascade to close membrane-
bound ion channels.  This in turn decreases ion flux and causes the cell to 
hyperpolarize (Hargrave and McDowell 1992; Yau 1994).  This cascade occurs 
simultaneously in thousands of opsin molecules per photoreceptor cell.  Since 
photoreceptors are arranged in parallel in the eye, the extracellular currents sum 
together and can be recorded externally from the cornea.  When photoreceptor 
cells hyperpolarize they cease the synaptic release of neurotransmitter to second 
order neurons, which causes these bipolar cells to depolarize.  The resulting 
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current can be recorded as the positive electrical potential of the ERG called the 
b-wave (Figure 1-5) (Green and Kapousta-Bruneau 1999; Gurevich and 
Slaughter 1993; Stockton and Slaughter 1989).  Increasing the intensity of the 
light stimulus results in a larger number of photons absorbed by the 
photoreceptors and a larger number of transmissions to bipolar cells.  This 
results in larger summed currents from each cell layer, which is reflected in the 
ERG by an increase in amplitude of the corresponding waveform components. 
 
 
Figure 1-5:  Characteristic ERG waveform components.  The a-wave is the early 
negative component of the ERG and reflects activity of the retinal photoreceptor 
cells.  The positive electrical potential of the ERG is called the b-wave, which 
reflects activity of cells in the inner retina.  
 
1.4. Large Animal Models  
Animal models of human disease play an important role in the understanding 
of disease mechanisms and in the development of treatment methodologies.  
While mice have several advantages such as low cost, short reproductive time, 
large litter size, and the opportunity for genetic modification, they are limited in 
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their ability to accurately approximate human disease.  Large animals such as 
dogs are more genetically, anatomically, and physiologically similar to people 
and fill a critical role as models for human disorders.  Large animal models also 
allow for longitudinal studies to determine long-term safety and efficacy of 
therapeutic interventions that are not possible in rodents.  In addition, proper 
scaling of treatment is much easier and more accurate in large animals.  While 
there is a 1000-fold difference in size between the brain of a mouse and that of a 
newborn child, there is only a 10-fold difference between a small dog and child 
(Casal and Haskins 2006).   
1.4.1 Canine Models 
The dog is the most widely studied large animal model for genetically 
inherited diseases; over 350 canine genetic diseases have been identified 
(Sargan 2004).  A large majority of genetic diseases are true orthologues of 
human disease with mutations identified in the analogous gene in both dogs and 
people (Ostrander and Giniger 1997).  Dogs have been invaluable for the 
understanding of disease pathogenesis for a variety of diseases including retinal 
degeneration (Veske et al. 1999; M. L. Katz et al. 2008), multiple lysosomal 
storage disorders (Bond et al. 2013; Ray et al. 1998), hemophilia (Herzog et al. 
1999), immunodeficiency (Felsburg et al. 1998), and neoplasia (Bianco et al. 
2003; Chauvet et al. 1998).  Canine models for many of these diseases exist in 
research colonies which provides the opportunity for thorough characterization of 
the disease phenotype and evaluation of treatment approaches.   
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1.4.2 Differences in the Human and Canine Visual Systems 
Axons of the retinal ganglion cell neurons coalesce to form the optic disc and 
course in the optic nerve.  The fibers of the visual pathway and PLR are both part 
of the optic nerve.  At the optic chiasm, axons originating from the medial (nasal) 
retina decussate and continue as the contralateral optic tract.  Axons from the 
lateral (temporal) retina remain ipsilateral (do not cross at chiasm) and course in 
the ipsilateral optic tract.   
The degree of decussation at the optic chiasm varies in different species.  As 
a general rule, the more lateral the eyes are located on the head, the greater the 
degree of decussation and the less vision is binocular.  In primates, essentially all 
the fibers from the medial half of the retina cross, while all the fibers from the 
lateral half of the retina remain ipsilateral enabling binocular vision.  In 
carnivores, all of the fibers from the medial retina decussate in addition to 
approximately half of the fibers of the lateral retina.  In people, 50% of the optic 
nerve fibers cross at the optic chiasm, while 75% of fibers decussate in dogs. 
Mammals have both a direct PLR in the stimulated eye, and a consensual PLR in 
the contralateral, unstimulated eye.  This is due to the decussation of fibers at the 
optic chiasm and a second decussation at the pretectal nuclei.  The unequal 
decussation in dogs results in a contraction anisocoria, or a difference in pupil 
constriction between the stimulated eye (direct) and the contralateral, 
unstimulated eye (consensual) (Scagliotti 1999).  This prominent anisocoria is 
not present in people since optic nerve fibers decussate evenly.  
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 Dogs and people also differ in spectral sensitivity due to a difference in 
retinal photopigments.  While both human and canine retinas contain rod, cone, 
and ipRGC photopigments, these pigments differ in the wavelengths of light to 
which they are most sensitive.  The human retina has a rod peak sensitivity of 
500 nm and three types of cones with peak sensitivities at 564 nm, 533 nm, and 
437 nm (Bowmaker and Dartnall 1980; Roorda and Williams 1999).  The dog has 
a rod peak sensitivity at 508nm and two cones with peak sensitivities at 429nm 
and 555nm (Neitz et al. 1989).  Melanopsin has been shown to have peak 
sensitivity around 480 nm in people, non-human primates (Gamlin et al. 2007), 
and mice (Hattar et al. 2003) though it hasn’t specifically been studied in the dog.    
1.5. Neuronal Ceroid Lipofuscinosis 
1.5.1 Human NCLs 
The neuronal ceroid lipofuscinoses (NCLs) are a group of lysosomal storage 
disorders that are inherited in an autosomal recessive manner (Haltia and 
Goebel 2012).  Currently, there are at least 14 different forms of NCL.  
Historically, the NCLs were classified by age of onset and by the ultrastructure of 
the accumulated storage material in the lysosomes (Haltia 2006),  but with the 
identification of the causative mutations, the NCLs are now being classified 
based on the identity of the gene in which the mutation resides (Mole et al. 
2011).    While symptoms do vary amongst the different forms of NCL, most 
cases manifest with cognitive and motor impairment, vision loss, seizures, and 
premature death.  These symptoms invariably worsen with age as the disorders 
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progress.  Disease progression in NCL correlates with an increase in abnormal 
storage material and neuronal degeneration.  
 A late-infantile onset form of NCL (CLN2) is caused by a mutation in the 
CLN2 gene which codes for tripeptidyl peptidase-1 (TPP1), a soluble, lysosomal 
enzyme that aids degradation of peptides in cells throughout the body.  
Specifically, TPP1 acts to cleave tripeptides at the N-terminal of larger peptides 
generated during lysosomal protein degradation (Tomkinson 1999).  In normal 
cells, proteins are regularly degraded into their component amino acids by a 
succession of several peptidases, including TPP1.  These free amino acids can 
then be used for new protein synthesis and metabolic purposes.  Therefore, the 
role of TPP1 is quite important in maintaining the normal balance between 
synthesis and degradation within the cell.  The absence of TPP1 in the brain and 
retina leads to accumulation of proteins typically degraded by the enzyme and 
degeneration of neurons, thereby causing the symptoms associated with CLN2. 
1.5.2 Canine Model of CLN2 
A Dachshund model of CLN2 was developed and is currently being 
maintained at the University of Missouri.  Affected dogs are homozygous for a 
frameshift mutation in the TPP1 gene (the ortholog of the human CLN2 gene).  
The dogs have a single base pair deletion in exon 4 of the gene (of 13 exons 
total) that alters the reading frame of the messenger RNA and creates a 
premature stop codon.  Consequently, the protein is not made properly and the 
activity of TPP1 in the brain is eliminated (Awano et al. 2006b).  Analysis of the 
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storage bodies present in the tissue of affected dogs revealed that they consist 
mainly of curvilinear forms (Awano et al. 2006b).  This is consistent with the 
ultrastructure of storage bodies that accumulate in the human form of CLN2 
(Haltia 2006).  In addition, the dogs present with mental dullness and ataxia by 
6.5 months of age and extreme vision loss and myoclonic seizures by 8 months 
of age (Katz et al. 2008).  Euthanasia is typically necessary between 10 and 11 
months of age due to the progression of neurologic signs.  This strong 
resemblance to the human CLN2 makes these dogs an excellent disease model 
on which to test possible treatment options prior to beginning human clinical 
trials. 
1.5.3 Treatment Modalities   
Enzyme replacement therapy (ERT) has long been considered as a possible 
treatment for lysosomal storage disorders, and it has proved effective in treating 
human disease of the peripheral tissue (Beutler 2004).  However, due to the 
blood-brain barrier, systemic delivery of a missing enzyme has not been 
successful for disorders involving the central nervous system (CNS).  If the 
blood-brain barrier can be bypassed, then ERT may provide hope for treating 
CNS dysfunction seen in the NCLs.  One option is to inject the enzyme directly 
into the ventricular system of the brain.  Since the cerebrospinal fluid (CSF) 
circulates throughout the brain via the ventricular system and subarachnoid 
space, any injected enzyme should be distributed throughout the brain as well.  
The enzyme can then be taken up by cells through a process mediated by the 
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surface receptor for mannose-6-phosphate.  TPP1 is then transported by the 
endosomal system to the lysosome allowing it to restore normal function in 
protein degradation.  
In a mouse model of late-infantile NCL, intraventricular enzyme replacement 
resulted in increased TPP1 activity throughout the brain (Chang et al. 2008).  
Treated mice exhibited a slowed progression of tremor development and a 
reduction in GFAP staining.  GFAP is the principle component of astrocytic 
intermediate filaments.  In the NCLs, over-expression of GFAP has been 
observed as a sign of astrocytic activation and gliosis that accompany neuronal 
degeneration (Xu et al. 2010).  The presence of autofluorescent storage material 
was also reduced in the treated mice compared with untreated, affected mice.  
While these results are certainly promising, this study was limited by the fact that 
TPP1 was only delivered over the course of 2 weeks.  Complications with glial 
scarring around the cannula resulted in seizures, which precluded the use of 
survival as a measure of outcome (Chang et al. 2008).  The treatment clearly 
requires long term testing and more thorough evaluation of outcome in a larger 
animal model before human clinical trials can be performed.  Therefore, the NCL 
Dachshund model is currently being used to investigate intraventricular / 
intrathecal delivery of the TPP1 enzyme and its ability to rescue the NCL 
phenotype.  
 Gene therapy may offer a treatment option using a principle similar to that of 
enzyme replacement therapy.  Viral-mediated gene therapy exploits the ability of 
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a virus to infect a cell and insert its DNA in the nucleus of that cell.  In gene 
therapy employing viral vectors, the genome of the virus is replaced with a 
desired therapeutic gene.  Adeno-associated viruses (AAV) are currently one of 
the most commonly used viruses for this purpose.  Unlike some viral vectors, 
AAVs are able to infect non-dividing cells such as neurons (Daya and Berns 
2008).  In AAV vectors used for gene therapy, the entire coding portion of the vial 
genome is removed, so there is no possibility of viral replication in transfected 
cells. 
 AAV-mediated gene therapy has been tested as a treatment in a mouse 
model of CLN2.  Increased TPP1 activity was observed up to 18 months after 
injection, no adverse reactions were noted, and a decrease in accumulated 
storage material was observed (Sondhi et al. 2007).  The mice also showed 
improvements in gait, seizure activity, and longevity.  These findings prompted a 
human clinical trial to study the safety of gene therapy in treating CLN2.  In this 
study patients received injections of an AAV-TPP1 vector into multiple locations 
within the brain parenchyma.  This trial was not designed to test efficacy, so it 
was not matched, randomized, or blinded and lacked a placebo/sham group.  It 
did, however, report an improvement in neurological performance (based on a 
clinical rating scale), while no improvement was seen in the MRI of the subjects 
(Worgall et al. 2008).  These results were somewhat promising, but more recent 
studies have failed to detect a therapeutic benefit in children treated in this 
manner (Ron Crystal, personal communication).  An alternative approach to 
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AAV-TTP1 mediated gene therapy for the CNS would be to transfect the 
ependymal cells that line the ventricular system with the vector.  With this 
approach, the TPP1 would be expected to be released into the CSF and then 
distributed throughout the brain via the CSF circulation.  The canine model of 
NCL provides a unique opportunity to study these approaches to treatment 
before human testing.  With the dog model, normal littermate controls (TPP1+/+) 
and untreated affected dogs are commonly available for comparison with respect 
to treatment efficacy. 
1.6. Study Objectives 
Disease progression in the canine model of CLN2 has been characterized 
with respect to the accumulation of storage material, neurologic symptoms, 
behavioral and cognitive changes, and decline in retinal function.  Quantification 
of the PLR may offer an additional biomarker for noninvasive, functional 
evaluation of neurons, both in the brain and the retina.  In addition to testing 
treatment efficacy in a canine disease model of NCL, objective PLR 
measurements may provide a method of monitoring disease progression and 
treatment in human patients as well.  Due to the non-invasive nature and 
flexibility of the PLR, it can be easily translated to monitor disease progression 
and treatment effects in human clinical trials.  The successful demonstration of 
PLR as an objective measure of neuronal function in dogs will introduce a useful 
tool for assessing therapeutic responses, thus helping to advance the 
development of lifesaving treatments for children affected by NCL.     
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The specific aims for this study are as follows: 
1. Develop PLR recording equipment and methodology capable of reliably 
quantifying the canine PLR. 
2. Characterize the normal canine PLR under varying stimulus conditions 
including a range of intensities, colors, and flash durations.  
3. Describe PLR deficits associated with CLN2 in the dog and evaluate the PLR 
as a potential biomarker of CLN2. 
4. Evaluate the efficacy of TPP1 enzyme replacement therapy in CLN2 
Dachshunds using PLR recordings. 
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CHAPTER 2  
INSTRUMENTATION AND RECORDING METHODS 
DEVELOPMENT 
2.1 Introduction 
Canine homologues of human hereditary retinal and neurological diseases 
have potential to serve as important models for developing better understanding 
of the mechanisms underlying disease and for testing treatment approaches.  
Mutations for many of these diseases have been identified since the canine 
genome became available (Veske et al. 1999; M. Katz et al. 2008; Acland et al. 
1999).  While electroretinography (ERG) is commonly used to assess retinal 
function in both dogs and people, the ERG only evaluates a small portion of the 
pathways involved in retinal mediated responses to light stimuli.  Therefore, the 
PLR and ERG complement one another for objective quantitative assessment of 
the retina and the integrity of neural pathways originating in the retina.   
To make optimal use of dogs as models for diseases affecting function of 
the retina and associated central nervous system pathways, objective non-
invasive measures to assess the functional integrity of these pathways, would be 
of great benefit.  Although the PLR has been widely used in people, 
pupillography has not been extensively studied in dogs or other large animals 
due to several obstacles.  Physical restraint of the animal during recording 
causes stress or anxiety, which can influence the PLR (Lowenstein and 
Lowenfeld 1950).  In addition, with a conscious, unsedated animal it is impossible 
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to keep the globe of the eye stationary, as is required for pupillography.  Unlike 
people, animals will not voluntarily maintain visual fixation on a target without 
extensive training.  
To overcome these barriers and facilitate the use of pupillography in 
evaluation of potential canine models of visual system and other neurological 
disorders, studies were undertaken to develop a reliable protocol for quantitative 
assessment of the PLR in dogs under varying stimulus conditions.  
2.2 Methods 
2.2.1 Animals 
Studies employed normal purpose-bred long-haired miniature Dachshunds 
(n=15) housed in a research facility at the University of Missouri. Prior to 
inclusion in the study, all dogs received a complete ophthalmic examination 
including vision assessment, slit lamp biomicroscopy, indirect ophthalmoscopy 
and retinal photography.  Dogs with evidence of vision compromise or ophthalmic 
conditions deemed threatening to vision were excluded.  Dogs were entrained to 
a 12:12 daily light cycle and were socialized daily in addition to receiving routine 
husbandry care.  All studies were performed in compliance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research and were 
approved by the University of Missouri Animal Care and Use Committee.   
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2.2.2 Experimental Design 
Dogs underwent PLR recordings using either injectable chemical restraint 
alone (sedation, neuroleptanalgesia, or dissociative anesthesia) (n=8), or using a 
combination of injectable sedation and inhalant anesthesia (n=7).  For the group 
that received injectable chemical restraint alone, each method described below 
was tested on at least two separate occasions in different dogs.  No single dog 
was subjected to recordings more often than once per week.  For dogs that 
received the combination of injectable chemical restraint and inhalant anesthesia, 
a standard PLR recording session was repeated in each dog every 2 months 
from 4 to 12 months of age, for a total of 5 recordings per dog.     
2.2.3 Chemical Restraint for PLR Recording 
Five methods of chemical restraint were assessed during quantitative 
evaluation of the PLR.  Four methods involved injectable chemical restraint only, 
and the fifth method utilized injectable sedation with inhalant anesthesia. For all 
methods, 30 minutes of dim light adaptation (0.9 lux broad spectrum, diffuse 
white light) preceded drug administration.  The methods employing only 
injectable chemical restraint are widely used in veterinary medicine and are as 
follows:  sedation with low-dose dexmedetomidine (5 µg/kg IM; Dexdomitor, 
Orion Corp., Espoo, Finland), sedation with high-dose dexmedetomidine (35 
µg/kg IM), dissociative anesthesia with dexmedetomidine (18 µg/kg IM)  and  
ketamine (3.5 mg/kg IM; KetaVed, Vedco Inc., Saint Joseph, MO) or 
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neuroleptanalgesia with dexmedetomidine (5 µg/kg IM) and butorphanol (0.17 
mg/kg IM; Torbugesic, Fort Dodge Animal Health, Overland Park, KS).   
For the combined injectable chemical restraint and inhalant anesthesia, 
dexmedetomidine (20-25 µg/kg IM) was given 30 minutes prior to induction of 
anesthesia with propofol (IV to effect, 1.49 ± 0.59 mg/kg (mean ± SD); PropoFlo 
28, Abbott Laboratories, Abbott Park, IL).  Dogs were intubated with a cuffed 
endotracheal tube and anesthesia maintained with isoflurane (1.5% vaporizer 
setting; Terrell, Piramal Healthcare, Boise, ID) in oxygen.  Vaporizer calibration 
was verified annually by an authorized anesthetic service technician.     
Heart and respiratory rates were monitored throughout all procedures, and 
body temperature was maintained between 98ºF and 101.5ºF using a heated 
circulating water blanket.  In addition during general anesthesia, dogs received 
intravenous fluids (5 ml/kg/hour; veterinary lactated ringer’s injection USP), and a 
portable multiparameter veterinary monitor (Cardell 9500 HD, Midmark Corp., 
Versailles, OH) was used to assess blood pressure, oxygen saturation, and end-
tidal CO2 levels throughout the procedure.   
The methods of chemical restraint were evaluated with regard to whether 
the level of restraint was adequate to perform the required procedures without 
causing stress to the dog.  Signs of stress in the dog included a sudden increase 
in respiration or heart rate and physical resistance to the placement of a 
speculum or stay suture.  Stability of the baseline pupil size was also evaluated.  
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2.2.4 PLR Recording Apparatus 
Recordings were performed with a custom apparatus (Figure 2-1) capable of 
timed delivery of a visible light stimulus from a mounted high-power light-emitting 
diode (LED) (MCWHL2/white, M625L2/red, M470L2/blue; Thorlabs Inc., Newton, 
NJ) and concurrent recording of pupil images at 30 frames per second using an 
infrared-sensitive camera (PC164CEX-2; Supercircuits Inc., Austin, TX) and 
continuous infrared illumination (880 nm LED) for visualization of the eye.   
Stimulus delivery and image capture were synchronized via an external data 
acquisition module and image acquisition PCI card and controlled by a custom 
software program written in LabVIEW (National Instruments Corp., Austin, TX).  
The system design is based on that of a custom pupillometer intended for human 
application (see Appendix A for complete parts list) (Fan et al. 2009b). 
 
2.2.5 PLR Recording Methods 
All recordings were done during the light period of the daily 12:12 light-dark 
cycle.  Dogs were kept in dim white light (0.9 lux) for at least 1 hour, including 
preparation time, and in complete darkness for 10 minutes prior to recording.  
After 30 minutes of dim light adaptation, dogs were subjected to either sedation 
alone or underwent general anesthesia as described above.  For all PLR 
recording sessions, the dog was positioned in sternal recumbency, with the head 
placed on a deflatable cushion.  The cornea of the right eye was anesthetized 
(0.5% proparacaine hydrochloride, Alcon Laboratories, Fort Worth, TX) and an 
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eyelid speculum was inserted to ensure that the nictitating membrane and 
eyelids did not interfere with light exposure or visualization of the pupil.  A small 
stay suture of 5-0 silk was placed in the bulbar conjunctiva on the central axis 
approximately 5 mm superior to the limbus to facilitate globe manipulation to 
maintain centration of the pupil on the optical axis of the recording apparatus.  
Suture ends were left long to be threaded between the outer surface of the eyelid 
and the lid speculum and clamped with a hemostat, which was draped over the 
top of the dog’s head and taped to the deflatable cushion in order to maintain a 
constant pupil position throughout recording (Figure 2-1).  The eye was regularly 
lubricated with saline eye wash solution throughout the procedure.   
 
Figure 2-1:  The camera and stimulus delivery portion of the PLR recording 
apparatus (left) and its schematic diagram (right).  See Appendix A for full parts list.  
Photograph was taken in normal room light after the procedure. 
 
The camera and LED stimulus delivery portion of the recording apparatus 
was mounted on a tripod and positioned 10 cm from the cornea (Figure 2-1) with 
the pupil centered in the image frame.  A piece of black fabric was draped over  
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the dog’s head and the camera throughout the procedure to ensure complete 
darkness, and the fabric was positioned directly over the untested eye to prevent 
any indirect pupil response in the eye of interest.   
2.2.6 PLR Stimulus Protocols 
The direct PLR of the right eye was evaluated using a standardized protocol 
(Table 2-1) of 100 millisecond flashes of white light at each of 10 intensities 
between 8 and 15 log photons/cm2/s (0.1 to 1400 lux).  In order to investigate the 
response of intrinsically photosensitive retinal ganglion cells (ipRGCs), the 
duration and color of the stimuli were altered for a second set of stimuli (Park et 
al. 2011; Gamlin et al. 2007).  PLRs were recorded in response to 1 second 
duration blue light stimuli (470 nm peak; 14.5 nm half-width) and 1 second 
duration red light stimuli (627 nm peak; 8.5 nm half-width).  Both red and blue 
stimuli were tested at two intensities, 13 and 14.6 log photons/cm2/s.   
Irradiance (µW/cm2/nm) and illuminance (lux) measurements were performed 
using a NIST-traceable calibrated spectroradiometer (ILT950, International Light 
Technologies, Peabody, MA) and irradiance values were subsequently converted 
to photon flux for the visible range.  Pupil images were recorded for 5 seconds 
before each flash and for 15 to 85 seconds after the flash depending on intensity 
of the light.  Time between flashes ranged from 1 minute with the dimmest flash 
to 4 minutes with the brightest flash to allow the pupil to return to baseline size.  
After dark-adaptation and positioning of the eye, the recording protocol required 
approximately 1 hour. 
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Stimulus Intensity 
Time between 
flashes 
Recording 
Time 
# of trials log photons/ 
cm2/s 
lux 
8 0.10 1 minute 30 seconds 3 
8.5 0.12 1 minute 30 seconds 3 
8.75 0.15 1 minute 30 seconds 3 
9 0.18 1 minute 30 seconds 3 
10 0.21 1.5 minutes 45 seconds 3 
11 0.30 2 minutes 45 seconds 3 
12 1.2 3 minutes 60 seconds 2 
13 10.8 3 minutes 60 seconds 2 
14 118 4 minutes 90 seconds 2 
15 1400 4 minutes 90 seconds 2 
 
Table 2-1:  PLR stimulus protocol.  All stimuli were presented as a 100 
millisecond flash of white light beginning with the dimmest flash and 
gradually increasing as outlined in the table.    
 
2.2.7 Baseline Pupil Measurements 
Four conscious, unrestrained dogs were dim light and dark adapted as 
described above.  Baseline pupil images were then captured using the infrared 
camera.  Holding the camera by hand, a short series of pupil images could be 
captured without restraining the dogs.   
2.2.8 PLR Image Analysis 
Pupil images were analyzed using the batch processing feature in 
Photoshop (CS6 extended; Adobe Systems Inc; San Jose, CA).  An “action” 
was created to calculate pupil area with a series of user-recorded steps (see 
Appendix B for detailed description).  First, the pupil was selected by defining a 
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pixel “color range” (Figure 2-2A).  The selection was then modified by the 
smooth command to eliminate extraneous pixels and then expanded and 
contracted by equal amounts to eliminate the hole in the selection caused by the 
reflection of light from the infrared LED off the surface of the cornea (Figure 
2-2B).  A list of image frame number and corresponding pupil area was exported 
to a spreadsheet and used to calculate desired parameters.  Area 
measurements were converted from pixels to mm2 based on the known size of 
the lid speculum present in each pupil image (Figure 2-2).    
 
Figure 2-2:  Photoshop analysis showing selection of the pupil (red hash marks) 
based on pixel color (A).  After expanding and contracting the selection by equal 
amounts, the hole in the selection caused by the infrared reflection is removed 
leaving an accurate outline of the pupil (B). 
 
2.2.9 Chemical Restraint for Electroretinography 
Dogs were deeply sedated with intramuscular administration of 
dexmedetomidine (30 - 40 µg/kg).  Ketamine (up to 5 mg/kg) was used in 
combination with the dexmedetomidine for dogs 6 months of age and younger to 
29 
 
achieve adequate sedation.  It was omitted in older dogs to reduce the risk of 
seizure associated with LINCL, and it was no longer necessary for adequate 
sedation with this age group.  Heart and respiratory rates were closely monitored 
throughout the procedure, and the dog was temperature controlled with a heated 
circulating water blanket. 
2.2.10 Electroretinography 
Beginning at 3 months of age, bilateral ERG evaluations were performed 
monthly using the Dog Diagnostic Protocol as described below (Katz et al. 2008).  
For ages at which dogs underwent PLR recording, ERG evaluation was 
performed within one week after the PLR recording session.   Prior to sedation, 
pupils were dilated with topical ophthalmic administration of 1% tropicamide, and 
dogs were prepared for recording in normal room light.  The dog’s head was 
positioned on a deflatable cushion to ensure complete stability.  The cornea was 
anesthetized with 1% proparacaine (Alcaine; Alcon), and a lid speculum was 
inserted to ensure that the nictitating membrane and the upper and lower eyelids 
did not interfere with light exposure of the maximally dilated pupils. In addition, a 
small stay suture was placed in the bulbar conjunctiva on the central axis 
approximately 5 mm superior to the limbus to facilitate globe manipulation to 
maintain centration of the pupil.  Platinum subdermal needle electrodes (Model 
E2; Grass Instrument Division, Astro-Med, Inc., West Warwick, RI) were used for 
the ground electrode, positioned on the occipital crest, and for the reference 
electrodes, positioned 3 to 4 cm from the lateral canthus, close to the base of 
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each ear. An active contact lens electrode (ERG-Jet; Universo Plastique, LKC 
Technologies Inc., Gaithersburg, MD) was placed on each cornea after 
instillation of one drop of 2% methylcellulose. The electrodes were connected to 
a preamplifier, and the signals were amplified with a band-pass filter between 0.3 
and 300 Hz. 
2.2.11 ERG Dog Diagnostic Protocol 
ERGs were bilaterally elicited and simultaneously recorded with a portable 
unit (HMsERG model 2000; RetVet Corp., Columbia, MO).  The right and left 
mini-ganzfeld domes were positioned approximately 2 cm from the 
corresponding eye.  The Dog Diagnostic Protocol is pre-programmed on the 
HmsERG unit and consists of scotopic and photopic ERGs, as recommended by 
the European College of Veterinary Ophthalmology, primarily for evaluation of 
rod and cone function (Narfström et al. 2002).  The details of the stimulus 
protocol are outlined in Table 2-2.  During 20 minutes of dark adaptation, 
scotopic low-intensity rod responses were elicited every 4 minutes at a stimulus 
intensity of 0.01 cd.s/m2.  Thereafter, scotopic responses were elicited using 3 
cd.s/m2 and 10 cd-s/m2 flashes to evaluate mixed rod and cone function.  After 
10 minutes of light adaptation with a background luminance of 30 cd.s/m2, 
photopic single-flash responses were recorded using 3 cd.s/m2 of flash stimulus, 
followed by evaluation of 30-Hz photopic flicker at the same light intensity. The 
latter two recordings were performed to evaluate cone and inner retina function, 
respectively.   
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Session 
Stimulus Intensity 
Session 
Duration 
Time 
Between 
Flashes 
# of 
averaged 
flashes 
log 
photons/ 
cm2/s 
cd.s/m2 
Dark adaptation 1   4 min.   
Rods recording 1 10.2 0.01  2 sec. 10 
Dark adaptation 2   4 min.   
Rods recording 2 10.2 0.01  2 sec. 10 
Dark adaptation 3   4 min.   
Rods recording 3 10.2 0.01  2 sec. 10 
Dark adaptation 4   4 min.   
Rods recording 4 10.2 0.01  2 sec. 10 
Dark adaptation 5   4 min.   
Rods recording 5 10.2 0.01  2 sec. 10 
Delay   2 sec.   
Rods & Cones –  
Standard Intensity 
12.65 3  10 sec. 4 
Delay   30 sec   
Rods & Cones –  
Hi Intensity 
13.2 10  20 sec. 4 
Light Adaptation 13.65 30 10 min   
Cones 12.65 3  0.5 sec 32 
Delay   2 sec   
Flicker – 30 Hz 12.65 3 4.1 sec 0.032 128 
 
Table 2-2:  ERG Dog Diagnostic Protocol.  Photon flux values (log 
photons/cm2/s) were calculated from irradiance levels measured with a 
NIST-traceable spectroradiometer.  
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2.2.12 ERG Scotopic Intensity Series 
For comparison of the ERG and PLR thresholds, a scotopic intensity series 
was performed in the right eye of 5 dogs.  Dogs were dim light adapted for 1 hour 
and dark adapted for 10 minutes prior to ERG recording; this is the same 
protocol used in PLR recording.  During dim light adaptation, dogs were prepared 
for recording as described in the previous section.  The scotopic 0, scotopic 1, 
and scotopic 2 intensity series (Table 2-3) are pre-programmed on the HmsERG 
unit and require the use of neutral density filters (ND 3 for Scotopic 0 and ND 2 
for Scotopic 1).  The intensity series stimuli ranged from 0.03 mcd.s/m2 to 30 
cd.s/m2 (7.65 to 13.65 log photons/cm2/s) with a 60 second delay between 
intensities.   
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Session 
Stimulus Intensity 
Time 
Between 
Flashes 
# of 
averaged 
flashes 
Delay 
after 
session 
log 
photons/ 
cm2/s 
mcd.s/m2 
Scotopic 0 7.65 0.03 2 sec. 10 60 sec. 
 8.2 0.1 2 sec. 10 60 sec. 
 8.65 0.3 2 sec. 10 60 sec. 
 9.2 1.0 2 sec. 4 60 sec. 
 9.65 3 2 sec. 4 60 sec. 
 10.2 10 2 sec. 4 60 sec. 
 10.65 30 10 sec. 4 4 min. 
Scotopic 1 8.2 0.1 2 sec. 10 60 sec. 
 9.2 1.0 2 sec. 10 60 sec. 
 10.2 10 2 sec. 10 60 sec. 
 10.65 30 10 sec. 4 60 sec. 
 11.2 100 10 sec. 4 4 min. 
Scotopic 2 11.2 100 10 sec. 4 60 sec. 
 11.65 300 10 sec. 4 60 sec. 
 12.2 1000 10 sec. 4 60 sec. 
 12.65 3000 10 sec. 4 60 sec. 
 13.2 10000  1 60 sec. 
 13.65 30000  1  
 
Table 2-3: ERG scotopic intensity series protocol.  Photon flux values 
(log photons/cm2/s) were calculated from irradiance levels measured 
with a NIST-traceable spectroradiometer.  
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2.2.13 Visually Evoked Potentials 
Immediately following an ERG session in which the dog had already been 
light adapted, the room lights were turned on (14.5 log photons/cm2/s or 400 lux) 
and the electrodes were repositioned for VEP recording.  Subdermal needle 
electrodes were placed over the occipital crest (active), on the forehead 
(reference), and 3 - 4 cm from the lateral canthus, close to the base of the right 
ear (ground).  VEPs were elicited bilaterally with 12.65 log photon/cm2/s flashes 
(3 cd.s/m2); 30 flashes were presented at 1HZ and the results averaged.  This 
protocol was repeated three times for a total of 90 flashes.  The averaged 
responses were evaluated for amplitude and implicit time.   
2.2.14 ERG and VEP Waveform Analysis 
ERG waveforms in all recordings were evaluated, and the amplitudes and 
implicit times for the a- and b-waves were measured as illustrated in Figure 2-3 
(Marmor et al. 2004).  VEP waveforms were analyzed for amplitude and implicit 
time of the peak occurring between 40 and 50 milliseconds after the flash (Figure 
2-4).  For analysis, data files were transferred to a computer from the memory 
card of the HmsERG unit and opened with the ERGVIEW software (v. 3220, 
Occuscience LLC, Kansas City, MO).  Amplitude and implicit time measurements 
were made using this software and then exported as a text file for further 
calculations.   
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Figure 2-3:  ERG waveform analysis.  The a-wave amplitude is measured as 
from the baseline to the trough of the a-wave, and the b-wave amplitude is 
measured from the trough of the a-wave to the peak of the b-wave.  The a-wave 
and b-wave implicit times are measured as the time from onset of the flash 
stimulus to the trough of the a-wave or the peak of the b-wave, respectively. 
 
 
Figure 2-4:  VEP waveform analysis.  The amplitude was measured for the 
peak occurring between 40 and 50 milliseconds after the flash.  Implicit time was 
measured as the actual time from the flash to the measured peak.   
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2.3 Results 
2.3.1 Effects of Sedation and General Anesthesia on the PLR 
With injectable chemical restraint alone, large spontaneous fluctuations in 
pupil size occurred independent of light stimulation (Figure 2-5).  This fluctuation 
was quantified by calculating the average pupil size from 20 seconds of baseline 
recording, calculating the deviation of each data point from this value, and computing the 
average deviation (Table 2-4).  Range was calculated as the difference between the 
maximum and minimum pupil size during the 20 second baseline recording (Table 2-4).  
Ventral rotation of the eye was also common, making visualization of the entire 
pupil difficult or impossible.  In all cases, eyelid interference with imaging was a 
problem and necessitated the use of an eyelid speculum.  However, low-dose 
dexmedetomidine did not provide adequate sedation to prevent the dog from 
resisting speculum placement.  In addition, under this light sedation the eye was 
only stationary for very short periods making it difficult to capture even a 10 
second series of images.  
The level of anesthesia achieved with combined injectable sedation and 
inhalant anesthesia was characterized by ventral rotation of the eye globes and a 
lack of response to external tactile and auditory stimuli.  This protocol produced a 
very consistent baseline pupil size with minimal noise (Figure 2-5D) and allowed 
for the use of an eyelid speculum and conjunctival stay suture for stable 
positioning of the eye without signs of stress in the animal.      
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Figure 2-5:  Baseline pupil size with different chemical restraint protocols; 
dexmedetomidine and ketamine (A) and dexmedetomidine and butorphanol (B).  
PLR traces from a dog under high-dose dexmedetomidine sedation (C) and a 
dog under general anesthesia (D).  Pupil responses are shown as percent of 
baseline pupil area.  No stimulus was used in traces (A) and (B).  A 100 
millisecond flash stimulus of 11 log photons/cm2/s was given 5 seconds into (C) 
and (D) recordings (dashed line) resulting in a large constriction.  The substantial 
spontaneous fluctuation in pupil size observed under injectable chemical restraint 
(A-C) was completely eliminated when the dog was anesthetized (D). 
 
Protocol 
# of 
trials 
Age (months) 
% Pupil Fluctuation 
(Avg ± SD) 
Range (%) 
(Avg ± SD) 
dexmedetomidine 
(high dose) 
5 6.8 ± 1.4 14.4 ± 1.8 49.0 ± 9.8 
dexmedetomidine /  
ketamine 
4 9.2 ± 0.5 10.6 ± 4.2 46.1 ± 0.2 
dexmedetomidine /  
butorphanol 
2 8.0 ± 1.5 13.6 ± 3.7 47.3 ±1.5 
isoflurane 7 10 ± 0.1 0.8 ± 0.5 2.7 ± 1.3 
 
Table 2-4:  Baseline pupil fluctuation as a percent of average pupil size for the 
chemical restraint protocols tested.  Range is the difference between the 
maximum and minimum pupil size over a 20 second baseline recording.  Low-
dose dexmedetomidine did not allow for reliable recordings making it impossible 
to quantify these measures.          
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The differences between chemical restraint alone and the addition of inhalant 
anesthesia were further illustrated by a trial in which the dog was sedated prior 
to general anesthesia and baseline recordings were taken before starting 
isoflurane administration and at timed intervals after initiating isoflurane 
administration.  The pupil was small and fluctuating in size with sedation alone.  
Within 10 minutes of beginning isoflurane administration, the pupil almost 
doubled in size and ceased fluctuating (Figure 2-6).      
 
Figure 2-6: Baseline pupil behavior with different chemical restraint protocols.  
The dashed trace shows the fluctuating pupil size from a dog under 
dexmedetomidine sedation.  The solid traces are from the same dog 3, 7, and 
10 minutes after isoflurane anesthesia was initiated and show the gradual 
progression to a stable baseline pupil. 
 
2.3.2 PLR Recordings 
Average baseline pupil diameter in conscious, unrestrained dogs was 10.06 
± 0.54 mm (mean ± SEM).  Baseline pupil diameter under general anesthesia 
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was 8.04 ± 0.16 mm, which was a significant reduction from that of awake dogs 
(p<0.001).  With a steady baseline pupil size under general anesthesia, it was 
possible to detect and reliably measure a PLR as small as 5% constriction.  All 
PLRs recorded under general anesthesia were characterized by four main 
phases including the steady state baseline pupil prior to the flash stimulus, the 
rapid pupil constriction in response to the stimulus, the initial redilation phase, 
and the slower secondary recovery to baseline pupil size (Figure 2-7).  As 
stimulus intensity was increased, the amplitude of pupil constriction also 
increased (Figure 2-7, Table 2-5).  Latency decreased with each increase of 
stimulus intensity.  Average constriction velocity and initial redilation velocity 
increased with stimulus intensity between 8 and 11 log photons/cm2/s, but then 
declined slightly with each subsequent increase in intensity (Table 2-6).  The 
kinetics of these responses are similar to those of PLRs recorded in people using 
a similar system.(Fan et al. 2009a)  The PIPR was detectable with a stimulus of 
11 log photons/cm2/s and increased with each subsequent increase in stimulus 
intensity (Figure 2-7, Table 2-5).       
To assess reproducibility of the PLR constriction amplitudes, the average 
from all dogs, at each stimulus intensity, was compared between the 5 recording 
sessions (Table 2-5).  For each stimulus intensity between 10 and 15 log 
photons/cm2/s, average constriction amplitude was repeatable across the 5 
sessions within a range of 5%.  Dim flashes from 8 to 9 log photons/cm2/s 
produced more variable constriction amplitudes (Table 2-5).     
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Figure 2-7:  PLR traces illustrating the range of pupil constriction observed in 
anesthetized dogs with 100 millisecond white light stimuli of increasing intensity 
(from top to bottom: 8, 8.5, 9, 13, and 15 log photons/cm2/s).  Pupil responses 
are shown as percent of baseline pupil area.  The stimulus onset occurred 5 
seconds into each recording.    
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Stimulus 
Intensity 
(log 
photons/
cm2/s) 
Age (months) 
Range 
(%) 4 6 8 10 12 
8 1.05 ± 0.61 1.24 ± 0.88 1.81 ± 1.21 1.36 ± 0.69 1.86 ± 1.5 0.81 
 
8.5 11.94 ± 4.68 8.46 ± 2.95 5.92 ± 4.76 13.46 ± 5.21 7.6 ± 2.73 7.53 
8.75 18.77 ± 6.33 17.26 ± 5.32 8.48 ± 6.1 24.7 ± 7.65 15.46 ± 4.3 16.22 
9 28.67 ± 5.28 29.09 ± 5.19 22.3 ± 7.5 31.58 ± 6.37 26.64 ± 6.37 9.28 
10 40.68 ± 3.05 42.2 ± 4.97 38.81 ± 6.35 43.06 ± 3.73 39.91 ± 3.23 4.25 
11 50.51 ± 2.52 50.47 ± 3.76 49.69 ± 4.78 51.15 ± 2.88 49.52 ± 2.26 1.63 
12 57.3 ± 2.56 55.73 ± 3.47 57.28 ± 4.3 57.85 ± 2.35 55.81 ± 1.81 2.11 
13 58.81 ± 3.34 58.49 ± 3.18 63.01 ± 4.55 62.39 ± 3.47 59.87 ± 2.12 4.52 
14 64.41 ± 5.23 61.71 ± 3.6 61.83 ± 5.13 63.28 ± 2.71 63.2 ± 3.32 2.70 
15 65.55 ± 3.96 68.26 ± 3.78 68.67 ± 4.47 68.82 ± 3.4 63.9 ± 3.3 4.92 
Table 2-5: PLR constriction amplitude shown as percent of baseline pupil area 
(average ± SEM).  Range is the difference between the maximum and minimum 
average constriction amplitude for the five ages tested.  
 
Stimulus 
Intensity (log 
photons/cm2/s) 
PLR Parameter (Average ± SEM) 
Latency (ms) 
Constriction 
Speed (mm/s) 
Redilation 
Speed (mm/s) 
PIPR (%) 
8 380.56 ± 26.66 0.5 ± 0.08 0.16 ± 0.02 -- 
8.5 328.47 ± 11.79 1.06 ± 0.14 0.38 ± 0.04 -- 
8.75 283.33 ± 8.95 1.47 ± 0.16 0.49 ± 0.05 -- 
9 265.28 ± 6.96 1.93 ± 0.15 0.66 ± 0.06 -- 
10 228.45 ± 3.74 2.54 ± 0.08 0.91 ± 0.06 4.72 ± 1.57 
11 209.43 ± 2.98 2.82 ± 0.06 1.06 ± 0.06 7.29 ± 0.79 
12 198.48 ± 3.86 2.69 ± 0.07 0.93 ± 0.06 17.38 ± 2.12 
13 191.4 ± 3.78 2.53 ± 0.1 0.85 ± 0.06 26.77 ± 2.99 
14 188.69 ± 5.08 2.54 ± 0.11 0.8 ± 0.07 30.71 ± 3.48 
15 183.33 ± 3.16 2.28 ± 0.09 0.59 ± 0.05 44.4 ± 3.77 
Table 2-6:  PLR parameters as a function of stimulus intensity in 
anesthetized dogs.  Values from all ages were averaged.  
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Red and blue stimuli resulted in robust PLRs with both intensities tested 
(Figure 2-8).  With stimuli of 13 log photons/cm2/s, the PLRs to red and blue light 
were very similar to one another for both the constriction and redilation phases.  
However, with stimuli of 14.6 log photons/cm2/s, red and blue light resulted in 
very different redilation phases.  While the pupil redilated quickly after offset of 
the red stimulus, pupil constriction persisted after offset of the blue stimulus 
(Figure 2-8).  This sustained constriction was present for at least 60 seconds 
after the stimulus.  
 
Figure 2-8: Blue and red traces show PLRs to 1 second stimuli of the 
corresponding color (top, 13 and 13.5 log photons/cm2/s; bottom, 14.5 and 15 log 
photons/cm2/s).  The onset of each stimulus occurred 1 second into each 
recording.  With stimuli of 13 and 13.5 log photons/cm2/s, the PLRs to red and 
blue light are very similar.  The brighter blue stimulus (14.5 log photons/cm2/s) 
results in sustained pupil constriction, while the pupil quickly redilates after a red 
stimulus of comparable intensity.  Recordings were performed in anesthetized 
dogs. 
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2.3.3 ERG & PLR Thresholds 
The ERG assessments demonstrated normal retinal function in all dogs 
throughout the 8 month period in which PLR recordings were obtained.  The 
threshold stimulus intensity for the PLR was 8.59 ± 0.30 log photons/cm2/s 
(average ± SD), while the threshold for the ERG was 9.56 ± 0.20 log 
photons/cm2/s (Table 2-7, Figure 2-9).  The stimulus intensity required to elicit a 
threshold ERG response was significantly higher, by approximately 10 times 
compared with the stimulus required to produce a reliably detectable pupil 
constriction (p<0.00005).  The minimum intensity required to elicit a recordable a-
wave was 11.2 log photons/cm2/s (Table 2-7). 
Stimulus Intensity ERG amplitude (µV) 
mcd.s/m2 log photons/cm2/s b-wave a-wave 
0.03 7.65 -- -- 
0.1 8.2 -- -- 
0.3 8.65 -- -- 
1 9.2 6.9 ± 3.4 -- 
3 9.65 45.9 ± 8.8 -- 
10 10.2 107.8 ± 14.3 -- 
30 10.65 154.6 ± 15.5 -- 
100 11.2 166.6 ± 17.6 20.1 ± 4.4 
300 11.65 207.8 ± 30 39.8 ± 8.3 
1000 12.2 244.1 ± 28.3 66.5 ± 12.4 
3000 12.65 264.4 ± 31.8 94.8 ± 14.5 
10000 13.2 258.7 ± 31.8 111.7 ± 15.1 
30000 13.65 286.5 ± 33.1 128.5 ± 16.7 
  
Table 2-7: ERG a- and b-wave amplitudes from the scotopic intensity series. 
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Figure 2-9:  Average PLR constriction amplitude and PIPR (n=7) and ERG a- 
and b-wave amplitudes (n=5) in response to white light stimuli of increasing 
intensity.  Assuming a threshold for reliable detection of the PLR at 5% pupil 
constriction and for the ERG b-wave an amplitude of 10V, the ERG 
threshold is more than 10 times higher than the PLR threshold. Pupil 
constriction amplitude is shown as percent of baseline pupil area.  ERGs 
were recorded under dexmedetomidine sedation and PLRs were recorded 
under anesthesia with dexmedetomidine and isoflurane.  Error bars 
represent standard error of the mean (SEM). 
2.4 Discussion 
We have developed a recording system and protocol capable of reliably 
quantifying the PLR in the dog that can easily be adapted for use in other 
species.  The system provides great flexibility with respect to stimulus color, 
duration, and range of intensity allowing for thorough evaluation of many 
parameters known to affect the PLR.  
Due to similarities in size and anatomy between canine and human eyes and 
the similarities between these species in neural pathways between the eye and 
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brain, the dog is an excellent model for studying retinal-mediated responses to 
light stimuli (Sargan 2004; Casal and Haskins 2006)  Many diseases affecting 
these responses in people are recapitulated in dogs (Baehr and Frederick 2009).  
This makes dogs very useful for evaluating potential therapeutic interventions to 
treat diseases of the visual system.  For example, identification of a dog model of 
Leber congenital amaurosis and successful development of gene therapy in this 
model served as the basis for its subsequent use in people (Narfstrom, Katz, 
Bragadottir, et al. 2003; Acland et al. 2001; Hauswirth et al. 2008).  In people, the 
efficacy of such therapeutic interventions can be assessed by asking patients 
how well they can see.  Unfortunately, this is not possible with dogs or other 
animal models, and behavioral testing for visual function is often impractical.  
Thus, for most animal studies, assessment of visual system integrity is usually 
performed using ERG recordings, sometimes in conjunction with subjective 
observation of the PLR to a bright light stimulus.  The sensitivity of the ERG 
performed with the recording electrode placed on the surface of the cornea is 
limited, due in large part to the distance between the recording electrode and the 
retina in which the electrical signals are generated (Bui et al. 1998; Derwent et al. 
2006)  As our data illustrate, the threshold for the PLR (8.59 ± 0.30 log units) is 
much lower than that of the ERG (9.56 ± 0.20 log units).  In addition, people and 
dogs with non-recordable ERG responses can still retain useful vision and exhibit 
a PLR (Melillo et al. 2012).  Consequently, quantitative PLR measurements may 
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be able to detect useful effects of therapeutic interventions that are too small to 
be detected with the ERG. 
It should be noted that the ERG and PLR were recorded under different form 
of chemical restraint.  The conditions used for ERG recordings were those that 
have been well established and are currently in widespread use in veterinary 
clinical practice and research.  It is unlikely that the current standards for 
chemical restraint used for ERG recordings will be modified.  In addition, ERGs 
recorded in dogs under general anesthesia with isoflurane are greatly reduced in 
amplitude compared with ERGs recorded in the same dogs under sedation with 
dexmedetomidine (Lin et al. 2009).   Based on these considerations, we 
attempted to obtain the PLR recordings using methods of chemical restraint 
similar to that which is used widely for ERG recordings.  Unfortunately, as 
illustrated in our study, using the sedation protocol employed for ERG recordings, 
we were unable to obtain a stable baseline pupil size.  As a result, different 
protocols for chemical restraint will need to be used for ERG and PLR recordings 
in both research and clinical settings.  Given this limitation, our conclusions about 
the differences in thresholds between the ERG and PLR are valid for the 
conditions under which these recordings can practically be made under 
standardized conditions.   
Quantitative assessment of the PLR will enable sensitive detection of defects 
within the neural pathway that mediates this reflex.  However, PLR recordings 
alone will not pinpoint the causes of observed deficits.  Accurate interpretation of 
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the PLR data will require concurrent assessment of retinal function.  If retinal 
responses to light are abnormal, identification of defects in parts of the PLR 
pathway downstream from the retina will be difficult to identify.  However, if 
retinal function is normal, PLR abnormalities can be attributed to neurological 
pathology outside of the retina.  With animal models it will be possible to 
associate PLR alterations with neuroanatomical localization of pathology. 
For large animal recording, the system described here has several 
advantages over previously described methods for PLR assessment.  The 
protocol we developed allows for stable positioning of the eye and full 
visualization of the pupil at all times.  The average baseline pupil diameter 
achieved under anesthesia was similar to that reported in another canine study 
performed under medetomidine sedation (Grozdanic et al. 2007).  However, the 
maximum pupil constriction achieved under medetomidine sedation was only 
22% with a 0.2 second stimulus of 57 cd/m2 (285 cd.s/m2 or ~14.6 log 
photons/cm2/s).  In contrast, the protocol described here regularly achieved pupil 
constriction of greater than 60% using a comparable stimulus intensity.  This 
constriction amplitude is similar to values achieved in awake human subjects 
using an analogous recording system and stimulus (Fan et al. 2009b).   
Melanopsin, the ipRGC photopigment, has peak sensitivity at 480 nm, and 
these cells are slow to activation and have a high threshold (Gamlin et al. 2007).  
Below the ipRGC threshold, PLRs to blue and red light have been shown to be 
quite similar (Markwell et al. 2010).  However, when the ipRGCs are strongly 
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activated they cause a sustained pupil constriction persisting after light offset that 
is not seen with a red stimulus outside the melanopsin spectral sensitivity 
(Kankipati, Girkin, and Gamlin 2010; Markwell, Feigl, and Zele 2010).  We were 
able to replicate these findings (Figure 2-8) suggesting that these characteristics 
of melanopsin input to the PLR are conserved in the dog.   
The current study demonstrated a large difference between the use of 
sedation, neuroleptanalgesia, and dissociative anesthesia compared to general 
anesthesia with respect to baseline pupil size and spontaneous pupil fluctuation.  
Obtaining reliable PLR recordings using injectable chemical restraint alone was 
not possible due to spontaneous fluctuations in pupil size and movement of the 
eyes.  For a person or animal in a relaxed state with a fixed visual focus, the 
pupil typically reaches a steady size determined by the balance of input from the 
sympathetic and parasympathetic systems (Lowenstein and Lowenfeld 1950).  
The observed pupil fluctuation therefore indicates variable input from these two 
systems.  This instability may also reflect the fact that systemic drug levels 
change continuously after intramuscular administration (Dyck et al. 1993).  In 
contrast, the continuous delivery of isoflurane allowed greater control over the 
level of anesthesia and resulted in a stable pupil size that was maintained over 
the period necessary to complete the stimulus protocol.  In human PLR studies 
isoflurane reduced the baseline pupil size and significantly depressed the 
constriction amplitude of the PLR (Larson et al. 1991).  As the concentration of 
isoflurane was increased, pupil constriction was further suppressed with no 
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detectable PLR at 1% end-tidal isoflurane (Larson et al. 1991).  While we did 
observe a reduction in baseline pupil size relative to unsedated dogs, we 
regularly observed large PLR constriction amplitudes.  This difference from the 
human study could be due to the differences in the duration of anesthesia, which 
has been shown to affect pupil size and responsiveness (Tayefeh et al. 1997).  
While our PLR measurements were completed within 1.5 hours of initiating 
isoflurane, the human study measured the PLRs 3-5 hours after initiating 
isoflurane.  In addition, the PLRs observed in anesthetized dogs were very 
similar to those recorded in people who were not chemically restrained (Fan et al. 
2009a).  Under the conditions of this investigation, general anesthesia using 
isoflurane did not appear to significantly alter the canine PLR.  
The pupillography system used in these studies was constructed with readily 
available components and could be assembled by research laboratories or could 
be commercialized for application in clinical veterinary ophthalmology and 
neurology.  User control of stimulus characteristics and recording parameters 
allows great flexibility in probing various aspects of the visual system involved in 
the PLR and allows the system to be adapted for use in a variety of species.  
Varying the stimulus parameters also allows for the evaluation of relative 
contributions of the different retinal chromophores in initiating this reflex 
(Kankipati, Girkin, and Gamlin 2010;  Markwell, Feigl, and Zele 2010).  Objective 
PLR analysis could also aid in localizing disease-related abnormalities in 
neurological and ophthalmic disorders (Park et al. 2011).   
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CHAPTER 3  
PLR DEFICITS IN A CANINE MODEL OF CLN2 
3.1 Introduction 
Childhood-onset neuronal ceroid lipofuscinoses (NCLs) are autosomal 
recessively inherited lysosomal storage disorders characterized by progressive 
vision loss culminating in blindness, cognitive and motor decline, and seizures 
(Haltia and Goebel 2012; Mole, Williams, and Goebel 2011)  The NCLs are 
uniformly fatal. Clinical signs of NCL result from wide-spread progressive 
neurodegeneration that is accompanied by intracellular accumulation of 
autofluorescent storage bodies in nervous and other tissues, including the retina 
(Haltia 2006).  Currently, several approaches to therapy are under investigation, 
including gene and stem cell therapies in addition to direct enzyme replacement 
(Pierret, Morrison, and Kirk 2008; Hobert and Dawson 2006; Souweidane et al. 
2010). 
Development of effective therapeutic interventions will be facilitated by the 
availability of suitable animal models.  Naturally-occurring NCLs have been 
identified in several larger animal species, including dogs (Awano et al. 2006a; 
Awano et al. 2006b; Bond et al. 2013; Farias et al. 2011; Katz et al. 2005; Katz et 
al. 2011; O’Brien and Katz 2008; Palmer et al. 2011; Sanders et al. 2010).  
Among the canine NCLs is a form of the disease in Dachshunds which results 
from a null mutation in TPP1 that encodes the lysosomal enzyme tripeptidyl-
peptidase-1 (TPP1) (Awano et al. 2006b)  Human subjects with mutations in 
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TPP1 (CLN2) have a form of NCL (CLN2) in which neurological signs typically 
first appear between 2 and 4 years of age and progress to death, usually by the 
middle teenage years (Haltia and Goebel 2012; Mole, Williams, and Goebel 
2011).  Dachshunds that are homozygous for the TPP1 null mutation develop 
neurological signs similar to those observed in children with CLN2 and reach end 
stage disease between 10 and 11 months of age (Vuillemenot et al. 2011)  The 
retinal pathology associated with canine CLN2 has been previously described in 
a small group of Dachshunds (Katz et al. 2008).  Affected dogs exhibit marked 
deficits in ERG b-wave amplitude and significant thinning of the inner retina by 
disease end-stage (Katz et al. 2008). 
The ERG is widely used to assess retinal function in animals in which it is 
difficult to evaluate vision.  However, the ERG is relatively insensitive, and 
subjects with profoundly depressed ERG responses can retain significant visually 
mediated behavior (Acland et al. 2001; Melillo et al. 2012; Narfstrom et al. 2003a; 
Narfstrom et al. 2003b).  In addition, the ERG only measures responses of the 
retina itself to light stimuli and provides no information on the transmission of 
light-induced neural signals to the brain.  The pupillary light reflex (PLR) depends 
on both retinal function and the intactness of central neural pathways involved in 
mediating this response to light.  In addition, the PLR can be elicited with 
significantly dimmer stimuli than can the ERG (Whiting et al. 2013; Yao et al. 
2006).  Therefore, quantitative evaluation of the PLR can be used in conjunction 
with the ERG as a sensitive tool to evaluate the integrity of the entire complex 
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network of neuronal circuitry involved in modulating pupil size (Park et al. 2011; 
F. Fotiou et al. 2000).  Such a tool will be particularly useful in characterizing 
diseases such as CLN2 that involve pathological changes in both the retina and 
other areas of the central nervous system.  In these diseases, ideal therapeutic 
interventions would ameliorate both retinal and central nervous system signs and 
would therefore preserve both the ERG and the PLR.  In light of therapeutic 
studies currently under way with the Dachshund model of CLN2, studies were 
undertaken to determine whether the PLR is affected in this model and to assess 
the relationship of any changes in the PLR to disease-related ERG alterations. 
 
3.2 Methods 
3.2.1 Animals 
Studies employed purpose-bred long-haired miniature Dachshunds housed in 
a research facility at the University of Missouri.  Dogs were entrained to a 12:12 
daily light cycle and were socialized daily in addition to receiving routine 
husbandry care.  Dogs were genotyped at the TPP1 locus using an allelic 
discrimination assay and an Applied Biosystems real time PCR instrument 
(Applied Biosystems, Carlsbad, CA).  Dogs utilized in this study were either 
homozygous normal (TPP1 +/+) (n=14) or homozygous for the mutant allele 
(TPP1 -/-) (n=9).  Heterozygous carriers of the TPP1 mutation (TPP1 -/+) were 
used for breeding but were not evaluated for responses to light stimuli.  Seven of 
the normal and three of the affected dogs had an intraventricular (ICV) catheter 
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placed as part of another study.  Four of the normal dogs received infusions of 
recombinant TPP1 protein, which should not have any effect on the PLR in a 
genetically normal dog that already produces this protein (Vuillemenot et al. 
2013).  The remaining dogs with implanted ICV catheters received infusions of 
artificial CSF, which is an inert substance.  Infusions were repeated every 2 
weeks starting between 2 and 3 months of age (Vuillemenot et al. 2013).  All 
studies were performed in compliance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and were approved by the University 
of Missouri Animal Care and Use Committee.   
3.2.2 Ophthalmic Examinations 
Prior to inclusion in the study, all dogs received a complete ophthalmic 
examination, at 10-12 weeks of age.  Assessment of the globe at this age 
precedes any signs of retinal or neurological impairment due to CLN2 in the 
affected dogs (Katz et al. 2008).  Any dogs with evidence of visual compromise 
or other ophthalmic conditions deemed threatening to vision were excluded from 
the study (n=1).  Examinations were repeated monthly for CLN2-affected dogs 
and every other month for genetically normal dogs.  Examinations included 
visually-mediated behavioral assessment and slit lamp biomicroscopy (SL14; 
Kowa Co. Ltd., Tokyo, Japan).  Pupils were dilated with a short-acting mydriatic 
(tropicamide 1%; Alcon, Fort Worth, TX), and indirect ophthalmoscopy (12500, 
Welch Allyn Inc., Skaneateles Falls, NY, USA) was performed.  Fundus 
photographs were taken following each examination (NM-100; Nidek Co. Ltd., 
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Freemont, CA) and archived electronically.  Photos were reviewed to evaluate for 
small changes in retinal appearance. 
3.2.3 Electroretinography 
Beginning at 3 months of age, bilateral ERG evaluations were performed 
monthly as previously described (Katz et al. 2008).  For ages at which dogs 
underwent PLR assessment, ERG evaluation was performed within one week 
after the PLR recording session.  ERGs were bilaterally elicited and 
simultaneously recorded with a portable unit (HMsERG model 2000; RetVet 
Corp., Columbia, MO).  The right and left mini-ganzfeld domes were positioned 
approximately 2 cm from the corresponding eye.  Dogs were deeply sedated with 
intramuscular administration of dexmedetomidine (30 - 40 µg/kg) and prepared 
for the ERG session in ordinary room light.   Ketamine (up to 5 mg/kg) was used 
in combination with the dexmedetomidine for dogs 6 months of age and younger 
to achieve adequate sedation.  It was omitted in older dogs to reduce the risk of 
seizure associated with CLN2, and it was no longer necessary for adequate 
sedation with this age group.   
Each ERG session consisted of scotopic and photopic ERGs in accordance 
with the Dog Diagnostic Protocol, recommended by the European College of 
Veterinary Ophthalmology, primarily for evaluation of rod and cone function 
(Narfström et al. 2002).  During 20 minutes of dark adaptation, scotopic low-
intensity rod responses were elicited every 4 minutes at a stimulus intensity of 
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10.2 log photons/cm2/s (0.01 cd.s/m2).  Thereafter, scotopic responses were 
elicited using flashes of 12.65 and 13.2 log photons/cm2/s (3 cd.s/m2 and 10 
cd.s/m2) to evaluate mixed rod and cone function.  The eyes were then exposed 
to diffuse white light at a luminance of 13.65 log photons/cm2/s (30 cd.s/m2) for 
10 minutes immediately after which responses to single 12.65 log photons/cm2/s 
(3 cd.s/m2) flash stimuli were recorded.  This was immediately followed by 
evaluation of responses to 30-Hz photopic flicker stimuli at the same light 
intensity.  ERG waveforms in all recordings were evaluated, and the amplitudes 
and implicit times for the a- and b-waves were measured as previously described 
(Marmor et al. 2004).   
3.2.4 PLR Recordings 
The PLR was recorded in each dog at 4, 6, 8, 10, and 12 months of age.  
CLN2-affected dogs were typically euthanized at 10 to 11 months of age due to 
progression of neurologic deficits, so the 12 month recordings were not obtained 
in these dogs.  The 10 month recording was not obtained in three of the affected 
dogs due to the need for early euthanasia prior to 10 months of age.  All 
recordings were done during the light period of the daily 12:12 light-dark cycle.  
The detailed methods for obtaining the PLRs have been described previously 
(Whiting et al. 2013).  Dogs were kept in dim light (0.9 lux) for at least 1 hour, 
including preparation time, and in complete darkness for 10 minutes prior to 
recording.  After 30 minutes of dim light adaptation, dogs were pre-medicated 
with dexmedetomidine (20-25 µg/kg IM) prior to induction of anesthesia with 
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propofol (IV to effect, 1.49 ± 0.59 mg/kg (mean ± SD); PropoFlo 28, Abbott 
Laboratories, Abbott Park, IL).  Dogs were intubated with a cuffed endotracheal 
tube and anesthesia maintained with isoflurane (1.5% vaporizer setting; Terrell, 
Piramal Healthcare, Boise, ID) in oxygen.  The dog was positioned in sternal 
recumbency, with the head placed on a deflatable cushion.  The cornea of the 
right eye was anesthetized with proparacaine and a lid speculum was inserted to 
ensure that the nictitating membrane and eyelids did not interfere with light 
exposure or visualization of the pupil.  In addition, a small stay suture was placed 
in the bulbar conjunctiva on the central axis approximately 5 mm superior to the 
limbus to facilitate globe manipulation to maintain centration of the pupil on the 
optical axis of the recording apparatus.  The eye was regularly lubricated with 
saline eye wash solution throughout the procedure.   
Recordings were performed with a custom apparatus (Fan et al. 2009b) 
capable of timed delivery of a visible light stimulus from a mounted high-power 
LED (MCWHL2; Thorlabs Inc., Newton, NJ) and concurrent recording of pupil 
images at 30 frames per second using an infrared-sensitive camera (PC164CEX-
2; Supercircuits Inc., Austin, TX) and continuous infrared illumination (880 nm 
LED) for visualization of the eye.  The direct PLR of the right eye was evaluated 
using a standardized protocol of 100 millisecond flashes of white light at each of 
10 intensities between 8 and 15 log photons/cm2/s (0.1 to 1400 lux).   
Pupil images were analyzed using the batch processing feature in Photoshop 
(Adobe Systems Inc; San Jose, CA).  A list of image frame number and 
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corresponding pupil area was exported to a spreadsheet and used to calculate 
desired parameters including latency, constriction amplitude, and velocity of 
constriction and redilation.  Area measurements were converted from pixels to 
mm2 based on the known size of the lid speculum present in each pupil image. 
3.2.5 PLR Parameters 
The PLR parameters that are typically considered are illustrated in Figure 1-4.  
For the studies described here, baseline pupil diameter is the average pupil 
diameter in a dark-adapted dog, over a 1-second period before the light stimulus. 
PLR constriction amplitude is defined as the difference between baseline pupil 
diameter and minimum pupil diameter attained following the light stimulus.  
Latency is defined as the time between stimulus onset and the beginning of pupil 
constriction.  Average constriction velocity is calculated as the constriction 
amplitude divided by the constriction time, where constriction time is calculated 
between the beginning of pupil constriction and the minimum pupil diameter.   
Redilation of the pupil is biphasic with a fast initial redilation and slower 
secondary redilation.  Average redilation velocity is a measure of initial redilation 
and is defined as half the constriction amplitude divided by the time required for 
the pupil to redilate from its minimum diameter to half the baseline pupil size.  For 
the brightest flash (15 log photons/cm2/s), the rate of secondary redilation was 
calculated for the period from 15 to 85 seconds after light offset. 
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3.2.6 Statistical Analysis 
All statistical tests were performed using SigmaPlot (Systat Software Inc., 
San Jose, CA).  Data were subjected to the Shapiro-Wilk test to confirm normal 
distribution.  One-way analysis of variance (ANOVA) was used to test for any 
differences between the normal dogs that were untreated, those that received 
artificial CSF, and those that received TPP1 enzyme.  No difference was found 
amongst these groups, so all data from genetically normal dogs were combined 
to serve as the normal control group.   
Repeated measures 2-way ANOVA was performed with disease status and 
age as the two factors.   This test was used to determine if significant differences 
exist between the normal control group and the CLN2-affected group with 
respect to any of the calculated PLR parameters for a given stimulus intensity.  
This test also determined whether age had a significant effect on PLR 
parameters or if there was any significant interaction between age and disease 
status.  Follow-up pair-wise comparisons were performed with the Holm-Sidak 
correction (α=0.05) to control family-wise error rate.  The Pearson product-
moment correlation coefficient was also calculated to test for correlation amongst 
the PLR parameters of latency, constriction velocity, constriction amplitude, and 
redilation velocity.   
The same statistical methods were used to evaluate ERG parameters to 
determine whether differences exist between normal and affected dogs and 
whether age was significant factor.  
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3.2.7 Fluorescence Microscopy 
The neural pathway involved in mediating the PLR in the dog includes the 
pretectal nucleus and the parasympathetic neurons of the oculomotor nucleus, 
so disease-related changes in these would be expected to affect the PLR.  
Therefore, analyses were performed to determine whether these neurons exhibit 
the accumulation of autofluorescent storage material that is characteristic of the 
NCLs. 
Regions of the brain containing these neurons were collected shortly after 
euthanasia and incubated in 0.1% glutaraldehyde, 3.5% paraformaldehyde, 0.13 
M sodium cacodylate, and 0.1 mM CaCl2 (pH 7.4) with gentle agitation for 
approximately 24 hours.  The samples were then incubated in 0.17 M sodium 
cacodylate, pH 7.4  with gentle agitation for at least 1 hour, embedded (Tissue-
Tek; Sakura Finetek, Torrance, CA), and frozen on dry ice. 
Five micrometer thick sections were cut from the Tissue Tek–embedded 
samples and mounted on glass slides (Super Frost; Fisher Scientific, Pittsburgh, 
PA) in 0.17 M sodium cacodylate. The sections were examined with a 
microscope (Axiophot; Carl Zeiss Meditec, Inc., Dublin, CA) equipped with epi-
illumination from a high-pressure, 50-W mercury vapor lamp, a 40X objective 
lens (Plan-Neofluar) with a 1.3 numerical aperture, a 395- to 440-nm band-pass 
exciter filter, a chromatic beam splitter (FT 460), and an barrier filter (LP 515; all 
from Carl Zeiss Meditec, Inc.). Photography was performed with an Olympus 
DP72 digital camera. 
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3.3 Results 
3.3.1 Ophthalmic Examinations 
 
Initial examination in all dogs revealed normal adnexal and ocular structures.  
Some affected mutant (TPP1 -/-) dogs developed progressive multifocal retinal 
detachment lesions consistent with CLN2 between the ages of 5 and 10 months 
(n=6) (Pearce et al. 2012).  Other affected dogs retained phenotypically normal 
fundus exams throughout the study period (n=3).  Homozygous normal (TPP1 
+/+) dogs had consistently normal ophthalmic examinations throughout the study 
period. 
3.3.2 ERG 
The ERG a-wave was relatively well preserved in CLN2-affected dogs (Figure 
3-1, Figure 3-2).  Scotopic recordings did begin to show a decrease in a-wave 
amplitude at 8 months of age, and the difference between normal and affected 
dogs was statistically significant at 10 months of age (Figure 3-1, Figure 3-2A).  
CLN2-affected dogs exhibited substantial deficits in the b-wave amplitude of both 
scotopic and photopic recordings (Figure 3-1, Figure 3-2).  Significant deficits in 
b-wave amplitude from rod recordings were present at 3 months of age.  By 6-7 
months of age, the rod response b-wave was non-recordable in affected dogs 
after 20 minutes of dark adaptation (Figure 3-2C).  Scotopic recordings reflecting 
mixed input from rods and cones illustrated a progressive decrease in b-wave 
amplitude, with significant deficits beginning at 5 months of age (Figure 3-2D).  
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Cone-mediated b-wave deficits were statistically significant beginning at 4 
months of age and deficits continued to progress with age, though cone 
responses remained recordable through 10 months of age (Figure 3-2E).  Cone 
inner retinal function, as illustrated by the b-wave amplitude of photopic flicker 
recordings, was significantly reduced in CLN2-affected dogs beginning at 5 
months of age.  While the deficits in flicker-induced b-wave amplitude persist 
through end-stage disease, this response remained recordable through 10 
months of age (Figure 3-2F).    
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Figure 3-1:  Representative ERG & VEP tracings from a 10 month old normal 
dog (left), 6 month old affected dog (middle) and 10 month old affected dog 
(right).  (A) Scotopic rod recordings and 10 cd.s/m2 mixed rod and cone 
recordings.  (B) Photopic cone single flash and 30 Hz flicker recordings.          
(C) VEP recordings performed on light-adapted dogs.  
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Figure 3-2:  ERG amplitudes as a function of age in normal and CLN2-affected 
dogs.  ERG a-wave amplitude from 10 cd.s/m2 scotopic (A) and photopic (B) 
recordings.  Significant deficits in a-wave amplitude are not present until 10 
months of age and only with scotopic recordings.  ERG b-wave amplitude from 
scotopic rod responses (C), scotopic mixed responses from rods and cones at 10 
cd.s/m2 (D), and photopic cone (E) and 30 Hz flicker recordings (F). Significant 
deficits in b-wave amplitude exist even in early stages of disease (†, p<0.001; *, 
p<0.005; ‡, p<0.05).  Error bars represent SEM.   
 
Results of the VEPs recordings were quite variable in both normal and 
affected dogs.  No statistical differences were found between normal and 
affected dogs.   
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Figure 3-3:  VEP amplitude as a function of age in normal and CLN2-affected 
dogs.  Results were variable with no statistical differences between normal and 
affected dogs.  Data at 11 months of age reflects a single affected dog.   
 
3.3.3 PLR 
No significant difference was found in baseline pupil diameter between 
normal dogs, 8.12 ± 0.15 mm and CLN2-affected dogs 8 months of age or 
younger, 8.13 ± 0.16 mm (mean ± SEM).  However, 10 month old CLN2-affected 
dogs had a significantly smaller (p<0.01) baseline pupil diameter than normal, 
6.97 ± 0.40 mm (Figure 3-4).  Normal dogs showed no age-related changes in 
any of the evaluated PLR parameters.  For both normal and affected dogs, there 
was a significant correlation between PLR constriction amplitude and each other 
parameter including latency, constriction velocity, and initial redilation velocity 
with correlation coefficients (r) greater than 0.8 (p<0.00001). 
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PLR constriction amplitude was reduced in CLN2-affected dogs compared 
with that of normal dogs for stimuli between 8.5 and 13 log photons/cm2/s (Figure 
3-5, Figure 3-6) when data were combined for dogs of all ages.  For stimuli 
between 9 and 11 log photons/cm2/s, constriction amplitude was already reduced 
from normal by 6 months of age (p<0.03) and further reduced at 8 months 
(p<0.02) and 10 months (p<0.001) of age.  With a stimulus of 12 log 
photons/cm2/s, constriction amplitude was significantly reduced beginning at 8 
months of age.  For stimuli of 8.5, 8.75, and 13 log photons/cm2/s, the group of 
affected dogs as a whole was significantly reduced from the normal group with 
respect to constriction amplitude (p<0.02), but age was not a significant factor for 
these intensities.  In addition, constriction amplitude from 10 month old CLN2-
affected dogs was significantly reduced from that of 4 and 6 month old dogs for 
stimuli between 10 and 12 log photons/cm2/s (p<0.001), and reduced from that of 
8 month old dogs with a stimulus of 10 log photons/cm2/s (p<0.001). 
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Figure 3-4: Baseline pupil diameter in anesthetized normal and CLN2-affected 
Dachshunds between 4 and 10 months of age.  Baseline diameter is significantly 
reduced in 10 month old affected dogs (*, p<0.01). 
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Figure 3-5:  Representative PLR traces from a normal dog at 10 months of age 
and a CLN2-affected dog between 4 and 10 months of age.  Pupil responses are 
shown as percent of baseline pupil area.  PLRs are in response to stimuli of 9, 
10, 11, and 15 log photons/cm2/s (A-D, respectively). 
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Figure 3-6:  PLR constriction amplitude as a function of stimulus intensity in 
normal and CLN2-affected dogs.  Amplitudes from normal dogs include 
combined data from dogs of all ages examined.  For stimulus intensities 
between 9 and 11 log photons/cm2/s, constriction amplitude of affected dogs 
was progressively reduced from normal; differences were significant beginning 
at 6 months of age (†, p<0.03).  With a stimulus of 12 log photons/cm2/s, 
constriction amplitude was not significantly reduced until 8 months of age (‡, 
p<0.02).  Age was not a significant factor for stimuli of 8.5, 8.75, and 13 log 
photons/cm2/s, but constriction amplitude of the CLN2-affected group as a whole 
was significantly reduced from normal (*,p<0.02).  Error bars represent SEM. 
 
For both normal and affected dogs, PLR latency decreased as stimulus 
intensity increased (Figure 3-7).  Average latency in normal dogs ranged from 
320 milliseconds with a stimulus of 8.5 log photons/cm2/s to 185 milliseconds 
with a stimulus of 15 log photons/cm2/s.  The PLR latency was significantly 
increased in 10 month old CLN2-affected dogs with stimuli between 8.75 and 11 
log photons/cm2/s (p<0.01).  With a stimulus intensity of 10 log photons/cm2/s, 
69 
 
latency was significantly increased by 8 months of age (p<0.02).  PLR latency 
data from 10 month old CLN2-affected dogs was significantly increased from that 
of 4 and 6 month old affected dogs with stimulus intensities of 9 and 10 log 
photons/cm2/s (p<0.01).     
 
Figure 3-7:  PLR latency as a function of stimulus intensity.  Latency is 
significantly longer in CLN2-affected dogs at 10 months of age for stimuli of 
8.75, 9, and 11 log photons/cm2/s (*, p<0.01) and by 8 months for a stimulus of 
10 log photons/cm2/s (†, p<0.02).  In addition, the increase in PLR latency was 
significantly greater in the 10 month old CLN2-affected dogs compared with 4 
and 6 month old dogs for stimuli of 9 and 10 log photons/cm2/s.  Error bars 
represent SEM. 
 
In both normal and CLN2-affected dogs, average constriction velocity of the 
PLR increased with increasing stimulus intensity from 8 to 11 log photons/cm2/s 
at which point it began to decrease slightly with each additional increase of 
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stimulus intensity (Figure 3-8).  Average constriction velocity was significantly 
reduced from normal in 10 month old CLN2-affected dogs with stimuli between 
8.75 and 11 log photons/cm2/s (p<0.001).  Constriction velocity in 10 month old 
affected dogs was significantly reduced from that of 4, 6, and 8 month old 
affected dogs (p<0.01).   
 
Figure 3-8:  Average constriction velocity was significantly reduced in 10 month 
old CLN2-affected dogs with stimuli between 8.75 and 11 log photons/cm2/s 
(*,p<0.001).  Error bars represent SEM.  
  
In both normal and CLN2-affected dogs, average PLR redilation velocity 
increased with increasing stimulus intensity from 8 to 11 log photons/cm2/s at 
which point it began to decrease slightly with each additional increase of stimulus 
intensity (Figure 3-9).  Average redilation velocities of 10 month old affected dogs 
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were significantly reduced from normal with stimuli between 8.75 and 11 log 
photons/cm2/s (p<0.005).  Redilation velocity in 10 month old affected dogs was 
also significantly reduced from that of 4, 6, and 8 month old affected dogs for a 
stimulus of 10 log photons/cm2/s (p<0.05).   
 
Figure 3-9: Average redilation velocity as a function of stimulus intensity.  
Redilation velocity is significantly reduced in 10 month old CLN2-affected dogs 
with stimuli between 8.75 and 11 log photons/cm2/s (*, p<0.005).  Error bars 
represent SEM.       
 
Analysis of sustained pupil size after a bright stimulus (15 log photons/cm2/s) 
revealed a significant delay (p<0.025) in secondary redilation of the pupil to 
baseline size in CLN2-affected dogs at 8 and 10 months of age (Figure 3-10).  
The rate of secondary redilation was significantly reduced in older affected dogs, 
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indicating that post-illumination pupil constriction persisted longer after light offset 
in these dogs than in normal dogs (Figure 3-10).   
 
Figure 3-10: The secondary redilation phase is delayed in CLN2-affected dogs 
at 8 and 10 months of age.  (A) Sample PLR traces from 10 month old dogs 
shown as percent of baseline pupil area.  The normal dog pupil gradually 
redilates to its baseline size while the pupil from the affected dog maintains its 
constricted size for 85 seconds after light offset.  (B) The rate of secondary 
redilation was decreased in older, affected dogs (*, p<0.025) indicating that 
constriction persists longer after light offset.   
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3.3.4 Fluorescence Microscopy 
Fluorescence microscopic examination of unstained sections of pretectal 
neurons and parasympathetic neurons of the oculomotor nucleus revealed a 
substantial accumulation of autofluorescent inclusions in both brain areas (Figure 
3-11).   This autofluorescent material was not present in the corresponding 
neurons from normal dogs. 
 
Figure 3-11:  Fluorescence micrographs of unstained cryostat sections of 
pretectal neurons (A, B) and the parasympathetic neurons of the oculomotor 
nucleus (C,D) from 10.5 month old normal (A,C) and CLN2-affected (B,D) 
Dachshunds. Yellow-emitting autofluorescent storage material was present in 
both brain regions of the CLN2-affected dogs. 
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3.4 Discussion 
In this study we have documented clear CLN2 disease-related alterations in 
both the ERG, which directly measures retinal function, and the PLR, which 
involves central processing of signals that originated in the retina.  
Characterization of these deficits in the canine model will be very useful in 
studies to assess the efficacy of therapeutic interventions for CLN2 that are 
currently underway.   
CLN2 results from the absence of or deficiency in TPP1,  a soluble lysosomal 
enzyme that can be taken up by cells after binding to cell-surface receptors and 
then transported to lysosomes via the endosomal system (Kyttälä et al. 2006).  
Therefore, like similar lysosomal storage disorders, CLN2 may be treatable with 
enzyme replacement therapy (ERT) (Vuillemenot et al. 2011).  Because the 
clinical signs of CLN2, other than vision loss, result almost exclusively from 
degeneration of the central nervous system, effective treatment of this disorder 
with ERT will require delivery of functional TPP1 to the brain and spinal cord.  
Proteins such as TPP1 do not enter the brain or spinal cord parenchyma from the 
bloodstream, so to be effective therapeutically, the enzyme will need to be 
delivered directly to these tissues.  In a previous study we have shown that TPP1 
infused into the cerebrospinal fluid (CSF) is widely distributed throughout the 
brain (Vuillemenot et al. 2011).  More recently, we have demonstrated that long-
term infusion of TPP1 into the CSF slows the progression of neurological signs in 
the Dachshund model of CLN2 (Katz et al. 2013).  Therefore, it appears that CSF 
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administration of TPP1 has great promise as a means of treating CLN2.  
However, it seems unlikely that TPP1 infused into the CSF will prevent retinal 
degeneration.  It is possible that TPP1 administered via the CSF will reach retinal 
ganglion cells via the optic nerve, which is in contact with the CSF, but uptake of 
the enzyme by other retinal cells via CSF administration seems unlikely.  Since 
retinal degeneration in the Dachshund CLN2 model is characterized primarily by 
loss of cells within the inner nuclear layer, CSF infusion of TPP1 is unlikely to 
prevent vision loss in this disease.  Therefore, to prevent retinal degeneration 
and preserve retinal function, it will probably be necessary to supply TPP1 
directly to the retina.  On the other hand, specific nuclei in the brain that are 
involved in the PLR would be expected to take up TPP1 from the CSF, so TPP1 
administration via CSF infusion may preserve the central pathways that mediate 
the PLR.  In the context of these therapeutic considerations, therefore, it is 
important to be able to assess both retinal function and the function of central 
pathways that are dependent on retinal input.   
Changes in the PLR of CLN2-affected dogs were apparent particularly with 
dim stimuli, including significant deficits in constriction amplitude, latency, 
constriction velocity, and initial redilation velocity which all depend largely on 
input from the parasympathetic system.  Given the strong correlation between 
constriction amplitude and these other parameters, deficits in all parameters are 
likely tied to one another and indicate reduced parasympathetic input to the PLR.  
The stimulus intensities with which deficits were observed are below the 
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threshold of melanopsin input indicating that the PLR response with these stimuli 
would be mainly driven by the rod/cone input (Lucas et al. 2003).  Lall et. al. 
(2010) found that cone input dominates the PLR with stimuli between 8 and 11 
log photons/cm2/s, while intrinsic melanopsin input dominates the PLR with 
stimuli greater than 11 log photons/cm2/s (Lall et al. 2010).   
CLN2-affected dogs also exhibited delays in the secondary redilation phase 
of the PLR and a reduction in baseline pupil size.  Each of these findings may 
point to a deficit in sympathetic input to the PLR.  Baseline pupil size is 
mediated by the sympathetic and parasympathetic innervation of the iris.  
Therefore, in order for the baseline pupil to be more constricted, the ratio of 
sympathetic input that promotes dilation to the parasympathetic input that 
promotes constriction must be reduced.  While sympathetic innervation to the 
iris is responsible for the slow secondary redilation to baseline pupil size, 
melanopsin input from the retina is responsible for the prolonged constriction 
that is typical after offset of a sufficiently bright stimulus (Kankipati, Girkin, and 
Gamlin 2010; Markwell, Feigl, and Zele 2010; Dacey et al. 2005b).  This 
sustained pupil constriction was present in both normal and affected dogs, 
indicating that the melanopsin pathway was still at least partially intact in the 
affected dogs.  However, it is possible that the reduced rate of secondary 
redilation in older affected dogs may reflect altered sympathetic input to the iris 
and/or altered input to the ipRGCs from OFF-bipolar and amacrine cells which 
both provide inhibitory input to the ipRGCs (Belenky et al. 2003; Brown and 
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Lucas 2009).  Since inner retinal cell function is severely impaired in CLN2, this 
apparent inability to moderate the prolonged melanopsin signal could result from 
a decrease or lack of the sustained synaptic inhibitory input that is normally 
present for ipRGCs (Belenky et al. 2003).   
The photoreceptor cell function, as reflected by ERG a-wave amplitudes, 
appears to be well preserved in CLN2-affected dogs.  However, the b-wave 
responses, mediated by both rods and cones, were severely depressed in the 
affected dogs, with cone-mediated responses being better preserved.  This is 
consistent with the previous report that CLN2-affected dogs exhibit significant 
thinning of the inner retinal layers while the photoreceptor layer remains relatively 
intact (Katz et al. 2008).  The decline in signal transmission from the 
photoreceptor cells reflected by the reduced b-wave responses would certainly 
be expected to contribute to PLR deficits in response to dim stimuli.  This is 
consistent with the fact that PLR deficits present between 6 and 8 months of age 
during the period in which ERG deficits progress most rapidly.  However, this 
does not rule out the possibility that the reduced PLR amplitudes resulted, at 
least in part, from pathological changes in the downstream neurological 
pathways involved in mediating the PLR.  This is particularly true since 
fluorescence microscopy illustrated those cellular changes characteristic of CLN2 
also occur in regions of the midbrain involved in the PLR (Figure 3-11).  In 
addition,  a study in mice lacking ON-bipolar cell transmission of the inner retina 
demonstrated less severe PLR deficits than those seen in mice lacking rod and 
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cone input (Thompson et al. 2011).  These facts combined with the low threshold 
of the PLR suggest that it is possible that even with reduced ERG b-wave 
amplitudes, the signals from the retina could have been sufficient to be 
associated with normal PLRs had the central neural pathways involved in 
mediating the PLR been functionally normal.  
The value of the VEP in assessing central processing of light-induced signals 
originating in the retina is less clear as no significant decreases in VEP 
amplitudes were observed despite substantial declines in ERG b-wave 
amplitudes.  The reasons for this seeming discrepancy are not apparent, but at 
least in dogs, visually-mediated behavior can be maintained in the face of 
significant declines in ERG amplitudes (Acland et al. 2001; Narfstrom et al. 
2003a; Narfstrom et al. 2003b).  This suggests that even reduced input from the 
retina may be sufficient to maintain the types of responses in the visual cortex 
that the VEP reflects. 
The characterization of disease-related alterations in light induced responses 
contributes to our understanding of the pathology underlying CLN2.  Preventing 
development of the deficits in the PLR and ERG responses can be used to 
objectively assess the efficacy of therapeutic interventions for CLN2 that are 
currently being evaluated.  An ideal therapy would prevent the declines in both 
the PLR and the ERG responses by preventing both retina and brain 
degeneration.      
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CHAPTER 4  
ENZYME REPLACEMENT THERAPY DELAYS CLN2-
RELATED PLR DEFICITS 
 
4.1 Introduction 
The TPP1 protein (tripeptidyl peptidase-1) is a soluble lysosomal enzyme that 
plays an important role in protein turnover.  Like other soluble lysosomal 
enzymes, TPP1 is not only localized within lysosomes, but is also secreted from 
cells and taken back up via cell surface receptors that recognize the mannose 6-
phosphate adducts which are common to enzymes that normally function within 
lysosomes (Figure 4-1).  After uptake from the cell surface, TPP1 is incorporated 
in active form into lysosomes (Kyttälä et al. 2006; Sohar, I., Sleat, D. E., Jadot, 
M. and Lobel 1999).  Therefore, in theory CLN2 should be amenable to TPP1 
enzyme replacement therapy.  TPP1 is synthesized on the rough endoplasmic 
reticulum as an inactive pro-enzyme.  Upon acidification in the lysosome, the 
protein is activated by cleavage of a peptide fragment from its amino terminal 
end.  Because large molecules such as TPP1 cannot cross the blood-brain 
barrier, delivery of the enzyme to the brain has been achieved through 
administration of pro-TPP1 by infusion into the cerebrospinal fluid (CSF) (Chang 
et al. 2008; Vuillemenot et al. 2011).  In the Dachshund CLN2 disease model, we 
have previously shown that this route of TPP1 administration results in 
widespread distribution of the active enzyme in many structures of the brain and 
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in reduction in the accumulation of neuronal lysosomal storage material that is 
characteristic of this disease (Vuillemenot et al. 2011; M. Katz et al. 2013).   
 
Figure 4-1:  Cellular transport of TPP1.  TPP1 can be synthesized and 
transported to the lysosome for use within a single cell, or it can be excreted and 
taken up by a neighboring cell.  With ERT, this results in the uptake and 
processing of infused TPP1 through normal cellular mechanisms. 
 
CLN2-affected dogs exhibit significant deficits in PLR latency, constriction 
velocity, constriction amplitude, and redilation velocity, particularly with dim light 
stimuli.  We hypothesize that these PLR deficits result in part from disease-
related degenerative changes in the CNS nuclei involved in mediating the PLR 
and that providing TPP1 to the CNS will ameliorate development of these 
deficits.  Studies were therefore undertaken to determine whether chronic 
administration of recombinant human pro-TPP1 into the CSF could ameliorate 
PLR deficits associated with CLN2.   
81 
 
4.2 Methods 
4.2.1 Animals 
Studies employed purpose-bred long-haired miniature Dachshunds between 
2 and 15 months of age.  Dogs were either normal (TPP1+/+ ; n=16) or CLN2-
affected (TPP1-/- ; n=17) as determined by genotyping at the TPP1 locus.  All 
studies were performed in compliance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and were approved by the University 
of Missouri Animal Care and Use Committee.   
4.2.2 Delivery of Replacement Enzyme 
Recombinant human pro-TPP1 (rhTPP1) was synthesized and purified 
as described previously (Vuillemenot et al. 2013; Vuillemenot et al. 2011)  
rhTPP1 was formulated in artificial CSF to concentrations of either 3.33 
mg/mL or 13.33 mg/mL.  Artificial CSF (vehicle) was administered alone to 
control dogs.  
At approximately 2 months of age two catheters were implanted in each dog.  
One catheter terminated in a lateral ventricle of the brain (ICV catheter) and the 
other in subarachnoid space at L5 (ITL catheter).  The catheters were connected 
to subcutaneous titanium access ports anchored in the fascia of the muscle and 
subcutaneous tissues of the cervical (ICV) and lumbar (ITL) regions.  Detailed 
descriptions of the catheter and port implantation procedures are provided 
elsewhere (Vuillemenot et al. 2013).   
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Starting 2 weeks after the catheter implantation surgeries, the test substances 
were administered via infusion through the ICV catheters once every other week.  
Three dogs were enrolled in each treatment group listed in Table 4-1.  Each 
infusion of vehicle or 4 mg rhTPP1 was performed over a 2 hour period.  
Infusions of 16 mg rhTPP1 were initially conducted over a 2 hour period, but the 
duration was increased to 4 hours to mitigate dosing reactions (Vuillemenot et al. 
2013).  Infusion of 48 mg rhTPP1 was performed over a 4 hour period for all 
infusions.  The 2 and 4 hour infusion rates were 0.6 or 0.3 mL/hour, respectively.  
Table 4-1: Experimental Treatment Groups 
Genotype Treatment 
TPP1+/+ Vehicle 
TPP1+/+ 4 mg rhTPP1 
TPP1+/+ 16 mg rhTPP1 
TPP1-/- Vehicle 
TPP1-/- 4 mg rhTPP1 
TPP1-/- 16 mg rhTPP1 
TPP1-/- 48 mg rhTPP1 
 
After 4 months of age, prior to each infusion, the location within the lateral 
ventricle and patency of the ICV catheter was assessed by computed 
tomography of the brain after infusion of 0.1 ml of the nonionic contrast agent 
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Iohexol (reference marker).  Over time the ICV catheter eventually either became 
occluded or the intraventricular portion migrated into the brain parenchyma due 
to growth of the cranial cavity.  When this occurred, the infusion site was 
switched from the ICV to the ITL catheter.  Eventually, the ITL catheters often 
became occluded as well.  When this occurred, the treatment administration was 
continued by bolus injection of the agent into the subarachnoid space at the 
cerebellomedullary cistern over 2 minutes. 
4.2.3 PLR & ERG Evaluation 
Standard PLR recording sessions were repeated in each dog receiving 
infusions every 2 months between 6 and 12 months of age.  All PLR recordings 
were performed under general anesthesia.  The ERG dog diagnostic protocol, as 
described in Chapter 2, was repeated monthly in each dog between 3 and 12 
months of age.  PLR and ERG recordings were also obtained at 15 months of 
age in two affected dogs treated with TPP1 and three normal dogs.   
Results from all genetically normal dogs (TPP1 +/+), including those that were 
left untreated (n=7), those that received infusions of vehicle (n=3) and those that 
received infusions of rhTPP1 (n=6), were combined to serve as the normal 
control group.  Results from CLN2-affected dogs that received infusions of 
vehicle (n=3) were combined with those from untreated, affected dogs (n=5) to 
serve as the disease control group.  Repeated measures 2-way ANOVA was 
used to compare results from affected dogs treated with infusions of rhTPP1 
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enzyme to each of these control groups to determine if enzyme replacement 
therapy was able to normalize any PLR or ERG deficits related to CLN2 disease 
progression. 
4.2.4 PLR Parameters 
Baseline pupil diameter was defined as the average pupil diameter, over a 1-
second period, before light stimulus. PLR constriction amplitude was defined as 
the difference between baseline pupil diameter and minimum pupil diameter 
occurring within 2.5 seconds after the stimulus.  Latency was determined as the 
time between stimulus onset and the beginning of pupil constriction.  Average 
constriction velocity was calculated as the constriction amplitude divided by the 
constriction time, or the time between the beginning of pupil constriction and the 
minimum pupil diameter.  Redilation of the pupil is biphasic with a fast initial 
redilation and slower secondary redilation.  Average redilation velocity was 
calculated for the initial redilation phase as half the constriction amplitude divided 
by the time required for the pupil to redilate from its minimum diameter to half the 
baseline pupil size.  For the brightest flash (15 log photons/cm2/s), the rate of 
secondary redilation was calculated for the period from 15 to 85 seconds after 
light offset. 
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4.2.5 Tissue Analysis 
Analyses were performed to determine whether the pretectal nucleus and 
parasympathetic region of the oculomotor nucleus in rhTPP1 treated dogs exhibit 
the accumulation of autofluorescent storage material that is characteristic of the 
NCLs or if treatment was able to reduce the amount of storage material.  These 
regions were also analyzed for presence of the rhTPP1 protein to determine if 
the infused enzyme was distributed to these tissues. 
For fluorescence microscopy, regions of the brain were collected shortly after 
euthanasia and incubated in 0.1% glutaraldehyde, 3.5% paraformaldehyde, 0.13 
M sodium cacodylate, and 0.1 mM CaCl2 (pH 7.4) with gentle agitation for 
approximately 24 hours.  The samples were then incubated in 0.17 M sodium 
cacodylate, pH 7.4  with gentle agitation for at least 1 hour, embedded (Tissue-
Tek; Sakura Finetek, Torrance, CA), and frozen on dry ice.  Five-micrometer-
thick sections were cut from the Tissue-Tek–embedded samples and mounted 
on glass slides (Super Frost; Fisher Scientific, Pittsburgh, PA) in 0.17 M sodium 
cacodylate. The sections were examined with a microscope (Axiophot; Carl Zeiss 
Meditec, Inc., Dublin, CA) equipped with epi-illumination from a high-pressure, 
50-W mercury vapor lamp, a 40X objective lens (Plan-Neofluar) with a 1.3 
numerical aperture, a 395- to 440-nm band-pass exciter filter, a chromatic beam 
splitter (FT 460), and an barrier filter (LP 515; all from Carl Zeiss Meditec, Inc.). 
Photography was performed with an Olympus DP72 digital camera. 
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For rhTPP1 analysis, tissue samples were collected shortly after euthanasia 
and were frozen immediately on dry ice.  The frozen samples were stored at        
-800C until analyzed for rhTPP1 concentrations.  The catalytically active form of 
rhTPP1 was measured in tissue homogenates using quantitative colorimetric 
enzyme linked immuno-absorbent assays (ELISAs).  These assays are specific 
for the recombinant human form of TPP1 and do not detect the endogenous 
canine TPP1 present in genetically normal animals.  The tissue ELISA has a limit 
of detection of 25 pg/mL and a range of 1.0-64 ng/mL in neat tissue homogenate.  
Tissue ELISA results were normalized to grams total protein in each 
homogenate, as determined with a BCA protein assay kit (Pierce, Rockford, IL). 
4.3 Results 
4.3.1 PLR 
 
CLN2-affected dogs that are left untreated exhibit significantly reduced PLR 
constriction amplitudes by 8 months of age with stimuli between 9 and 12 log 
photons/cm2/s (Figure 4-2, Figure 4-3).  These deficits are even more 
pronounced by 10 months of age (Figure 4-2, Figure 4-4).   
With all CLN2-affected dogs treated with rhTPP1 grouped together, these 
dogs have PLR constriction amplitudes that apparently begin to decrease from 
normal at 8 months of age, though the deficits are not as severe as those of 8 
month old untreated, affected dogs (Figure 4-3A).  The deficits then appear to 
progress further by 10 months of age (Figure 4-4A).  However, closer 
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examination of the data revealed a grouping among the treated dogs that did not 
depend on treatment dose level.  Three of the treated dogs (2 dogs treated with 4 
mg TPP1 and 1 dog treated with 16 mg TPP1) retained normal PLR constriction 
amplitude through 10 months of age (Group 1) (Figure 4-2), while the other 
treated dogs (Group 2) mimicked the deficits in constriction amplitude observed 
in untreated, affected dogs at both 8 and 10 months of age (Figure 4-3B, Figure 
4-4B).   
 
Figure 4-2:  Representative PLR traces from a normal dog, untreated CLN2-
affected dog, and an affected dog that received ERT between 8 and 15 months 
of age.  Pupil responses are shown as percent of baseline pupil area.  PLRs are 
in response to a stimulus of 10 log photons/cm2/s. 
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Figure 4-3: PLR constriction amplitudes from 8 month old dogs.  (A) Data from 
all CLN2-affected dogs treated with TPP1 enzyme replacement therapy is 
combined.  While untreated dogs have significant deficits compared to normal (#, 
p<0.02), treated dogs are not significantly different from normal or untreated 
dogs.  (B) Treated data is broken into 2 groups of dogs with Group 1 having 
normal constriction amplitudes that are significantly different from those of 
untreated, CLN2-affected dogs (*, p<0.001; †, p<0.01). 
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Figure 4-4:  PLR constriction amplitudes from 10 month old dogs.  (A) Data from 
all CLN2-affected dogs treated with TPP1 enzyme replacement therapy is 
combined.  Untreated dogs (#, p<0.02) and treated dogs (†, p<0.025) have 
significant deficits compared to normal. (B) Treated data is broken into 2 groups 
of dogs with Group 1 having normal constriction amplitudes that are significantly 
different from those of untreated, CLN2-affected dogs (*, p≤0.001; ‡, p<0.025). 
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By 12 months of age, treated dogs from Group 1 began to show PLR deficits 
that indicated a waning effect of the treatment (Figure 4-5).  However, 
constriction amplitudes in Group 1 were still significantly increased over those of 
Group 2 for stimuli of 9 and 10 log photons/cm2/s (p<0.05).   
 
Figure 4-5:  PLR constriction amplitudes from 12 month old CLN2-affected dogs.  
Amplitudes are reduced from normal in both Group 1 and Group 2, though Group 
1 amplitudes are still significantly greater (‡, p<0.05) than those of Group 2 for 
stimuli of 9 and 10 log photons/cm2/s. 
 
Deficits in PLR constriction amplitude at 15 months of age (Figure 4-6) were 
very similar for both dogs treated with rhTPP1 that survived to this age (one dog 
from each group).  However, the change between 12 months and 15 months of 
age was much more pronounced in the dog from Group 1 (Figure 4-6A).  PLR 
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threshold at 15 months of age was increased by over 3 log units from the 
average threshold for this group at 12 months of age.  For the 15 month old dog 
from Group 1, these changes coincided with end-stage disease.  However, the 
15 month old dog from Group 2 had only begun to show neurologic signs of 
disease.  Both 15 month old dogs had severe deficits in inner retinal function as 
illustrated by reduction of the ERG b-wave amplitude.       
Similar trends to those found with PLR constriction amplitude were observed 
for PLR latency, constriction velocity, and redilation velocity.  The group of CLN2-
affected dogs that received rhTPP1 and exhibited normal PLR constriction 
amplitude (Group 1) also had normal values for these parameters at 10 months 
of age (Figure 4-7).  
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Figure 4-6:  PLR constriction amplitude changes with age for rhTPP1 treated 
dogs from Group 1 (A) and Group 2 (B).  Group 1 shows a delay in PLR 
constriction amplitude deficits, but at 15 months of age, the dogs from each 
group exhibit very similar results.        
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Figure 4-7: PLR parameters in normal and 10 month old treated and untreated 
CLN2-affected Dachshunds.  Maximum constriction velocity (A), maximum 
redilation velocity (B), and latency (C) are all normalized in Group 1 of the 
treated dogs and are significantly different than untreated dogs with dim 
intensity stimuli (*, p<0.05). 
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Analysis of sustained pupil size after a bright stimulus (15 log photons/cm2/s) 
revealed a significant delay (p<0.05) in secondary redilation of the pupil to 
baseline size in rhTTP1 treated CLN2-affected dogs (Figure 4-8), similar to 
deficits found in untreated dogs (Chapter 3).  There was no difference in this 
measure between Group 1 and Group 2 treated dogs.  The rate of secondary 
redilation was significantly reduced in treated affected dogs than in genetically 
normal dogs between 8 and 12 months of age, indicating that post-illumination 
pupil constriction persisted longer after light offset in these dogs than in normal 
dogs.   
 
Figure 4-8: The secondary redilation phase of the PLR is delayed in treated 
CLN2-affected dogs between 8 and 12 months of age.  The rate of secondary 
redilation was significantly decreased (*, p<0.05) indicating that constriction 
persists longer after light offset in these dogs than in normal dogs. 
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4.3.2 ERG and VEP 
Deficits in both scotopic and photopic ERG b-wave amplitudes of CLN2-
affected dogs that were treated with rhTPP1 were very similar to those of 
untreated, affected dogs (Figure 4-9).  No improvement was seen in b-wave 
amplitudes of Group 1 dogs compared with either untreated dogs or treated dogs 
from Group 2.    
The amplitudes of the VEPs elicited under photopic conditions were quite 
variable in both normal and affected dogs.  Dogs treated with rhTPP1 showed no 
clear difference from those of untreated, affected dogs. 
 
96 
 
 
 
Figure 4-9: ERG a-wave (A,B) and b-wave (C-F) amplitudes as a function of 
age in normal and CLN2-affected Dachshunds.  ERG deficits are similar in 
CLN2-affected dogs that were untreated and those that received TPP1 ERT.  
ERG a-wave amplitude from 10 cd.s/m2 scotopic (A) and photopic (B) 
recordings.  ERG b-wave amplitude from scotopic rod responses (C), scotopic 
mixed responses from rods and cones at 10 cd.s/m2 (D), photopic cone 
recordings (E), and photopic 30 Hz flicker recordings (F).  Treated dogs from 
Group 1 that exhibited normal PLR constriction amplitudes, exhibit no 
improvement in ERG b-wave amplitude.  Error bars represent SEM.   
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Figure 4-10:  VEP amplitudes as a function of age.  Results were variable and 
no differences were apparent amongst the treatment groups. 
 
4.3.3 Tissue Analysis 
rhTPP1 enzyme was detectable in both the pretectal nuclei and 
parasympathetic nuclei of the oculomotor nucleus in 4 of 5 treated dogs that 
were examined (the tissue from 1 dog was not analyzed).   Fluorescence 
microscopic examination of unstained sections of the pretectal nucleus and the 
nuclei of the parasympathetic division of the oculomotor nucleus of treated 
CLN2-affected dogs revealed a much lower prevalence of autofluorescent 
inclusions in neurons in both nuclei when compared with untreated dogs (Figure 
4-11).   This autofluorescent material was not present in the corresponding brain 
areas from normal dogs.   
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Figure 4-11:  Fluorescence micrographs of unstained cryostat sections of the 
pretectal nucleus (left column; A,C,E) and the parasympathetic division of the 
oculomotor nucleus (right column; B,D,F) from normal dogs (A,B), untreated 
CLN2-affected dogs (C,D) and affected dogs treated with rhTPP1 (E, F). Yellow-
emitting autofluorescent storage material was present in the neurons of both 
nuclei in the untreated CLN2-affected dogs (white arrows).  While some storage 
material was present in the dogs treated with rhTPP1, it was much less prevalent 
and unlike the untreated dogs, there are neurons that do not appear to contain 
this material (red arrows). 
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4.4 Discussion 
Based on the results from this study, it appears that pro-TPP1 delivered 
directly to the brain via the CSF has the ability to delay PLR deficits associated 
with CLN2 in a Dachshund model, despite the fact that these treatments did not 
inhibit the decline in retinal function as assessed with the ERG.  The group of 
CLN2-affected dogs that showed treatment effects had normal PLR constriction 
amplitude through 10 months of age and didn’t begin to display deficits until 12 
months of age.  This is a great improvement when compared with untreated dogs 
which began to exhibit deficits by 6 months of age that progressed through end-
stage disease at 10 months of age. 
The PLR depends on the function of both the retina and specific nuclei in the 
midbrain.  All of these tissues exhibit an accumulation of disease-related storage 
material in CLN2-affected dogs.  Based on the CSF circulation, the only retinal 
neurons that may be expected to obtain rhTPP1 infused into the CSF would be 
the ganglion cells which may be able to take up the enzyme from the CSF that 
bathes the optic nerve.  It is unlikely that any significant amount of TPP1 was 
able to reach the cells of the inner nuclear layer of the retina, which undergo 
severe degeneration in CLN2 (Katz et al. 2008).  Consistent with this 
expectation, rhTPP1 administered via the CSF did not result in any improvement 
in the ERG b-wave, which reflects activity of retinal neurons with cell bodies 
located in the retinal inner nuclear layer.  Therefore, it seems more likely that the 
infused enzyme was able to normalize the PLR by preventing degeneration in the 
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pretectal and oculomotor nuclei.  Consistent with this possibility is the 
observation that the accumulation of autofluorescent lysosomal storage bodies in 
neurons in these brain nuclei appeared to be reduced in affected dogs treated 
with TPP1.  In addition, analysis of the pretectal and oculomotor nuclei obtained 
at necropsy from the treated dogs indicated that the enzyme infused into the CSF 
did reach these brain nuclei. 
Results of this study were variable with only one-third of the subjects 
exhibiting a treatment effect on the PLR.  This may be due to variability in 
treatment delivery route, as the number of infusions for each route (ICV, ITL, 
bolus injection) differed for each dog.  In addition, the exact distribution pattern of 
TPP1 via the CSF may have been different for each dog resulting in varying 
treatment effects.  Such variability would be expected based on the known flow 
dynamics of the CSF.  The fact that only some dogs responded to the treatment 
with preservation of the PLR indicates that this therapeutic effect is possible with 
CSF administration of TPP1, but that it will be important to identify the variables 
that determine efficacy. 
Both treated and untreated CLN2-affected dogs exhibited delays in the 
secondary redilation phase of the PLR.  Melanopsin input to the PLR is 
responsible for the prolonged constriction that is typical after offset of a 
sufficiently bright stimulus (Kankipati, Girkin, and Gamlin 2010; Markwell, Feigl, 
and Zele 2010; Dacey et al. 2005b).  It is possible that the reduced rate of 
secondary redilation in older affected dogs may reflect altered sympathetic input 
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to the iris, and/or altered effect on the ipRGCs from OFF-bipolar and amacrine 
cells which both provide inhibitory input to the ipRGCs (Belenky et al. 2003; 
Brown and Lucas 2009).   ERT was unable to normalize this phase of the PLR 
despite the improvement observed in other PLR parameters.  Since ERT was 
most likely unable to attenuate retinal degeneration, this may point to a lack of 
retinal inhibition as the source of these redilation abnormalities.  However, due to 
the variable distribution of TPP1 via the CSF of treated dogs, it is possible that 
sympathetic neurons involved in the slow redilation phase of the PLR did not 
receive therapeutic amounts of TPP1 in these dogs and degeneration of these 
areas contributed to the delays in secondary redilation.      
The timing of changes in the PLR associated with CLN2 do not coincide 
perfectly with changes in retinal function or with neurologic signs caused by 
neuronal degeneration.  In untreated dogs, mild PLR changes occur early in the 
disease at 6-8 months of age, which coincides with the most rapidly progressing 
deficits in the ERG and retinal function.  However, no large changes occur in the 
ERG after 8 months of age while the most extreme PLR deficits occur at 10 
months of age and coincide with the appearance of severe neurologic deficits.  In 
the dogs treated with ERT, the timing of retinal function deficits was not altered.  
These findings suggest that alterations in central neural pathways play a 
predominant role in the development of PLR deficits in canine CLN2.  The onset 
of neurologic signs was delayed in all ERT treated dogs, though only some also 
showed a delay in the onset of PLR deficits.  There is likely a complicated 
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interaction of the deficits in both the retina and other CNS areas involved in 
modulating the PLR, and further analysis of these tissues is needed to fully 
explain both the presence of the PLR deficits and the observed treatment effects 
based on distribution of the infused enzyme.            
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CHAPTER 5  
SUMMARY AND FUTURE DIRECTIONS 
We have developed a recording system and protocol capable of reliably 
quantifying the canine PLR.  The system provides great flexibility with respect to 
stimulus color, duration, and range of intensity allowing for thorough evaluation of 
many parameters known to affect the PLR. 
Using the developed system and methods, we have documented clear CLN2 
disease-related alterations in both the ERG, which directly measures retinal 
function, and the PLR, which involves central processing of signals that originate 
in the retina.  Changes in the PLR of CLN2-affected dogs were apparent 
particularly with dim stimuli, including significant deficits in constriction amplitude, 
latency, constriction velocity, and initial and secondary redilation velocity. 
Characterization of these deficits in the canine model enabled use of the PLR as 
a biomarker in assessing efficacy of therapeutic intervention. 
ERT with TPP1 delivered directly to the brain via the CSF has demonstrated 
the ability to delay PLR deficits associated with CLN2 in a Dachshund model.  
While the results were variable, the group of CLN2-affected dogs that showed 
treatment effects retained a normal PLR significantly longer than untreated dogs.  
Based on the known circulation of CSF and the lack of improvement in the ERG, 
it is most likely that ERT was able to normalize the PLR by preventing 
degeneration of pretectal and parasympathetic division of the oculomotor nucleus 
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and possibly the sympathetic neuronal pathway.  However, further analysis of 
retinal and other CNS tissues are needed to fully explain these treatment effects. 
While ERT has proven effective in delaying neurologic signs in the 
Dachshund model of NCL, it has limitations.  This method of enzyme delivery 
requires repeated administration throughout the life of the patient, which is 
cumbersome and costly.  In addition, the catheters implanted in the brain are 
invasive and prone to complications over time.   
Alternative methods of enzyme delivery are currently under consideration for 
long term treatment of both the neurologic and visual changes that occur in 
CLN2.  Direct TPP1 gene therapy targeted to the parenchymal cells lining the 
ventricles of the brain would allow the production of TPP1 and secretion directly 
into the CSF circulation.  In preliminary studies using this approach, we have 
been able to maintain at least normal sustained CSF TPP1 levels for several 
months after administration of the gene therapy vector.  Based on these 
preliminary studies, we plan to treat additional dogs and determine whether the 
gene therapy approach can also preserve the PLR in dogs with CLN2.  Another 
treatment method under development is the use of autologous mesenchymal 
stem cells which have been genetically modified to produce TPP1.  These cells 
can be injected into the vitreous of the eye or the ventricle of the brain for long 
term production of TPP1.  By treating both central and peripheral tissues affected 
by CLN2, this method has promise for ameliorating the most prominent 
symptoms associated with the disease.  For the ideal case in which a treatment 
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is able to prevent both neurologic and visual deficits, PLR quantification in this 
dog model will play a large role in demonstrating treatment efficacy.  
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APPENDIX A 
PARTS LIST FOR THE PLR RECORDING SYSTEM 
Super Circuits Inc, Austin, TX: www.supercircuits.com 
National Instruments Corp, Austin, TX: www.ni.com  
Thorlabs Inc, Newton, NJ:  www.thorlabs.com 
 
Part Number Part Name Quantitiy Company 
PC164CEX-2 Low Light Video Camera 1 Super Circuits 
DC12-1000R Power Supply 1 Super Circuits 
776670-35 LabView Software/Full  1 National Instruments 
778838-01 PCI Image card 1 National Instruments 
183882-02 IMAQ-BNC, image cable 1 National Instruments 
780116-01 DAQ Device, BNC Term 1 National Instruments 
B4C Cage Cube Platform 1 Thorlabs 
B1C Cover Plate  1 Thorlabs 
FM03 Cold Mirror 1 Thorlabs 
B5C Cage Cube Optic Mount 1 Thorlabs 
C6W Cage System Cube  1 Thorlabs 
CFH1 Filter Holder w/Plate 1 Thorlabs 
CFH1-F Extra Filter Holder 4 Thorlabs 
SM1A9 Thread Adapter  1 Thorlabs 
SM1T2 Coupler, External Threads 2 Thorlabs 
SM1D12C Ring-Activated Diaphragm 1 Thorlabs 
SM1NR05 Zoom Housing 1 Thorlabs 
SM1A2 Thread Adapter 1 Thorlabs 
SM2RR Retaining Ring 1 Thorlabs 
CP02 Cage Plate 1 Thorlabs 
SM1CP2M End Cap 3 Thorlabs 
SM1A6 Thread Adapter 1 Thorlabs 
SM05L03 Lens Tube 1 Thorlabs 
SM1L10 Lens Tube 1 Thorlabs 
CM1-BS013 Beamsplitter 1 Thorlabs 
LA1540-A Plano-Convex Lens 1 Thorlabs 
AC127-030-B Near IR Achromat Lens 1 Thorlabs 
NE510B Absorptive ND Filter, OD: 1 1 Thorlabs 
NE520B Absorptive ND Filter, OD: 2 1 Thorlabs 
NE540B Absorptive ND Filter, OD: 4 1 Thorlabs 
MCWHL2 Cold White Mounted LED 1 Thorlabs 
M470L2 Blue Mounted LED 1 Thorlabs 
M627L1 Red Mounted LED 1 Thorlabs 
TPS001 15 V Power Supply Unit 1 Thorlabs 
LEDD1A T-Cube LED Driver 1 Thorlabs 
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APPENDIX B 
PHOTOSHOP IMAGE ANALYSIS “ACTION” STEPS 
 Create a new action and record the following steps: 
o Use the elliptical marquee tool to select the general area of the 
image that contains the pupil. 
o Under the “Select” menu choose “Color Range…”   
o Click on the pupil using the eye dropper – choose a color that 
accurately selects the pupil. 
o Under the “Select” menu, choose “Modify” and then “Smooth”.  
Enter the number of pixels by which to smooth the selection -- 
typically between 1 and 5 pixels.  This should remove any 
extraneous pixels that have been selected but are not within the 
pupil. 
o Choose “Select”  “Modify”  “Expand”.  Enter the number of 
pixels by which to expand the selection – typically 50 pixels.  This 
needs to be large enough to remove the hole in the selection 
caused by the infrared reflection. 
o Choose “Select”  “Modify”  “Contract”.  Enter the number of 
pixels by which to contract the selection – this number must match 
the value used to expand the selection. 
o Under the “Analysis” menu, choose “Record Measurements”.  This 
will start a running record of area measurements and file name. 
o Close the image. 
 Stop the action recording. 
 
 Under the “File” menu, choose “Automate” and then “Batch”.  Then choose 
the Action to apply and browse for the file folder containing the images to 
analyze. 
 
 When the batch has finished, select all recorded measurements and export 
the values as a text file. 
 
 *Note:  Photoshop allows a maximum of 700 recorded measurements at one 
time.  Therefore, the images must be separated into groups of 700 prior to 
beginning batch processing.  A short program can be written and applied to 
each folder of images to do this automatically.    
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